WO2005095624A2 - Filamentous fungal mutants with improved homologous recombination efficiency - Google Patents

Filamentous fungal mutants with improved homologous recombination efficiency Download PDF

Info

Publication number
WO2005095624A2
WO2005095624A2 PCT/EP2005/051464 EP2005051464W WO2005095624A2 WO 2005095624 A2 WO2005095624 A2 WO 2005095624A2 EP 2005051464 W EP2005051464 W EP 2005051464W WO 2005095624 A2 WO2005095624 A2 WO 2005095624A2
Authority
WO
WIPO (PCT)
Prior art keywords
nhr
gene
mutant
dna
filamentous fungus
Prior art date
Application number
PCT/EP2005/051464
Other languages
French (fr)
Other versions
WO2005095624A3 (en
Inventor
Petrus Jacobus Theodorus Dekker
Van Den Marco Alexander Berg
Original Assignee
Dsm Ip Assets B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005095624(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to JP2007505561A priority Critical patent/JP2007530065A/en
Priority to EP18160034.7A priority patent/EP3351637B1/en
Priority to EP05740129A priority patent/EP1733040B1/en
Priority to DE602005023427T priority patent/DE602005023427D1/en
Priority to DK05740129.1T priority patent/DK1733040T3/en
Priority to US10/594,014 priority patent/US9243043B2/en
Priority to PL05740129T priority patent/PL1733040T3/en
Application filed by Dsm Ip Assets B.V. filed Critical Dsm Ip Assets B.V.
Priority to AU2005229437A priority patent/AU2005229437A1/en
Priority to CN200580011927.4A priority patent/CN101218348B/en
Priority to AT05740129T priority patent/ATE480632T1/en
Priority to CA002559827A priority patent/CA2559827A1/en
Publication of WO2005095624A2 publication Critical patent/WO2005095624A2/en
Publication of WO2005095624A3 publication Critical patent/WO2005095624A3/en
Priority to US14/980,425 priority patent/US9657301B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/38Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Aspergillus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/385Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Penicillium
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • C12N1/145Fungal isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10Nitrogen as only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P23/00Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P37/00Preparation of compounds having a 4-thia-1-azabicyclo [3.2.0] heptane ring system, e.g. penicillin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/645Fungi ; Processes using fungi
    • C12R2001/80Penicillium
    • C12R2001/82Penicillium chrysogenum

Definitions

  • the invention relates to the field of molecular biology. It particularly relates to methods to improve the efficiency of directed integration of nucleic acids into the genome of a filamentous fungus and uses thereof. Background of the invention
  • Eukaryotic cells are preferred organisms for (recombinant) production of polypeptides and secondary metabolites.
  • site of integration of the gene of interest coding for the protein to be produced is crucial for the regulation of transcription and/or expression of the integrated gene of interest. Since in most eukaryotic organisms integration of DNA into the genome occurs with high frequency at random, the construction of a protein production strain by recombinant DNA technology often leads to the unwanted random integration of the expression cassette comprising the gene encoding the protein to be produced. This uncontrolled "at random multiple integration" of an expression cassette is a potentially dangerous process, which can lead to unwanted modification of the genome of the host.
  • Eukaryotic cells have at least two separate pathways (one via homologous and one via non-homologous recombination) through which nucleic acids (in particular of course DNA) can be integrated into the host genome.
  • the yeast Saccharomyces cerevisiae is an organism with a preference for homologous recombination (HR).
  • HR homologous recombination
  • the ratio of non- homologous to homologous recombination (NHR/HR) of this organism may vary from about 0.07 to 0.007.
  • WO 02/052026 discloses mutants of Saccharomyces cerevisiae having an improved targeting efficiency of DNA sequences into its genome. Such mutant strains are deficient in a gene involved in NHR (KU70).
  • the NHR/HR ratio is ranged between 1 and more than 100.
  • targeted integration frequency is rather low.
  • the length of homologous regions flanking a polynucleotide sequence to be integrated into the genome of such organisms has to be relatively long for example at least 2000bp for disrupting a single gene and at least 500bp for screening putative transformants.
  • the necessity of such flanking regions represents a heavy burden when cloning the DNA construct comprising said polynucleotide and when transforming the organism with it.
  • neighbouring genes which lie within those flanking regions can easily be disturbed durhg the recombination processes following transformation, thereby causing unwanted and unexpected side-effects.
  • Figure 1 depicts the replacement vector pDEL-HDFA used to inactive the hdfA gene in Aspergillus niger (A. nige ⁇ .
  • the replacement vector comprises theft ⁇ '/ ⁇ flanking regions, the amoS marker and E. coli DNA.
  • the E. coli DNA was removed by digestion with restriction enzymes Ascl and Notl, prior to transformation of the A niger strains.
  • Figure 2 depicts the replacement vector pDEL-HDFB used to inactive the hdfB gene in A. niger.
  • the replacement vector comprises fie hdfB flanking regions, the amdS marker and E. coli DNA.
  • the E. coli DNA was removed by digestion with restriction enzymes Ascl and Notl, prior to transformation of the A. /./gerstrains .
  • Figure 3 depicts the strategy used to delete the hdfA gene of A. riger.
  • the DNA construct used comprises the a cfS selection marker flanked by homologous regions (5' and 3') of the hdfA gene (1).
  • This construct integrates through double homologous recombination (X) at the genomic hdfA locus (2) and replaces the genomic hdfA gene copy (3).
  • Subsequentiy, recombination over the direct repeats (J) removes the amdS marker, resulting in precise excision of hehdfA gene (4).
  • Figure 4 depicts the strategy used to delete the hdfB gene of A. niger.
  • the DNA construct comprises the amdS selection marker flanked by homologous regions (5' and 3') of the hdfB gene (1).
  • T is construct integrates through double homologous recombination (X) at the genomic ⁇ dfB locus (2) and replaces the genomic hdfB gene copy (3). Subsequently, recombination over the direct repeats J) removes the amdS marker, resulting in precise excision of the/7c//B gene (4).
  • Figure 5 depicts the schematic strategy used to integrate a DNA construct into the genome of A niger through single homologous recombination.
  • the expression vector comprises the selectable amdS marker and a gene of interest flanked by homologous regions of the glaA locus (3' glaA and 3" glaA respectively) to direct integration at the genomic glaA locus.
  • the present invention provides a method for increasing the efficiency of targeted integration of a polynucleotide to a pre-determined site into the genome of a filamentous fungal cell, with a preference for NHR, wherein said polynucleotide has a region of homology with said pre-determined site comprising steering an integration pathway towards HR.
  • the present invention arrives at such steering either by elevating the efficiency of the HR pathway, and/or by lowering (meaning reducing) the efficiency of the NHR pathway and/or by decreasing the NHR HR ratio.
  • the HR pathway is defined as all genes and elements being involved in the control of the targeted integration of polynucleotides into the genome of a host, said polynucleotides having a certain homology with a certain predetermined site of the genome of a host wherein the integration is targeted
  • the NHR pathway is defined as all genes and elements being involved in the control of the integration of polynucleotides into the genome of a host, irrespective of the degree of homology of the said polynucleotides with the genome sequence of the host.
  • the steering comprises providing a mutant of a parent filamentous fUngal cell, wherein the NHR/HR ratio is decreased in the mutant of at least 5% as compared to said ratio in said parent organism as measured by the following assay. More preferably, the NHR/HR ratio is decreased in the mutant of at least
  • tie filamentous fungal cell of the invention has a ratio NHR/HR, which is at least 200, at least 50, at least 10 as measured by the following assay.
  • the ratio of the filamentous fungal cell is at least 1, more preferably at least 0.5, even more preferably at least 0.1, even more preferably at least
  • the filamentous fungal cell of the invention has a ratio NHR/HR, which is less than 200, even more preferably less than 50, less than "10 as measured by the following assay. Even more preferably the ratio of the filamentous fungal cell is less than 1, even more preferably less than 0.5, even more preferably less than 0.1 , even more preferably less than 0.05, even more preferably less than O.O 1 even more preferably less than 0.005 even more preferably less than 0.001 even more preferably less than 0.0005 even more preferably less than 0.0001 and most preferably less than 0.00001.
  • the ratio of NHR HR is preferably measured by the assay as described in WO 02/052026 (table 2, p23).
  • the parent organism is one of the filamentous fungus cells as defined under the section host cell.
  • the filamentous fungus cell of the invention originates from a species as defined under the section host cell.
  • the NHR/HR ratio in a filamentous fungus is monitored using techniques known to the skilled person such as transcriptional profiling and/or northern blotting and/or western blotting of at least one of the following components involved in such pathways: KU70, KU80, MRE11, RAD50, RAD51, RAD52, XRS2, SIR4, LIG4.
  • a region of homology means "at least one" region of homology.
  • a pre-determined site is herein defined as a site within the genetic material contained by a host cell to which a polynucleotide with homology to this same site is integrated with a method according to the invention.
  • the invention provides a method for increasing the efficiency of targeted integration of a polynucleotide to a pre-determined site into the genome of a filamentous fungal cell with a preference for NHR, wherein said polynucleotide has a region of homology with said predetermined site comprising steering an integration pathway towards HR by providing a filamentous fungus, wherein the efficiency of the NHR pathway has been lowered and/or the NHR/HR ratio has been decreased compared to the efficiency of the NHR pathway and/or the NHR/HR ralo of the filamentous fungus it originates from under the same conditions.
  • the parent organism is one of the filamentous fungus as defined under the section host cell.
  • the efficiency of the NHR pathway is preferably measured in the assay as described in WO02/052026 (table 2, p23).
  • the efficiency of the NHR pathway in a filamentous fungus is monitored using techniques known to the skilled person such as transcriptional profiling and/or northern blotting and/or western blotting of components involved in such pathway. More preferably, the expression level of at least one of the following components is monitored: KU70, KU80, MRE11, RAD50, RAD51, RAD52, XRS2, SIR4, LIG54. Even more preferably, the expression level of homologous components of the KU complex is monitored. Most preferably, the expression level of homologous KU70 and/or KU80 is monitored.
  • a lowered NHR efficiency means at least lower than in the parenta cell the obtained cell originates from.
  • lowered means twice lower, more preferably ten times lower, even more preferably 10O times lower, most preferably more than 1000 times lower and even most preferably not detectable using northern or western blotting, array techniques or a phenotypic screen.
  • a typical phenotypic screen that could be used comprises the following steps: transforming the putative NHR mutants with an expression cassette comprising a selection marker gene flanked by homologous sequences of a predetermined genomic site.
  • the selection marker gene used in this phenotypic screen can be selected from a number of marker genes that are useful for transformation of filamentous fungi.
  • these markers include but are not limited to dominant and bi-directional selection marker gene such as an acetamidase IpmdS ) gene (EP 635 574 B or WO 97/06261), auxotrophic marker genes such as argB, trpC or pyrG and antibiotic resistance genes providing resistance against e.g.
  • phleomy ⁇ ' n (the product encoded by the ble gene confers resistence to phleomycine), hygromycin B or G418.
  • a preferred selection marker gene is the ble gene encoding a protein conferring resistence to phleomycin.
  • the putative NHR mutants already contain at this piedetermined genomic site a birectional selection marker gene such as an amdS gene, nitrate reductase gene (niaD), sulphate permease (Sut B) gene or PyrG gene.
  • the niaD gene has already been described elsewhere (Gouka RJ, van Hartingsveldt W, Bovenberg RA, van den Hondel CA, van Gorcom RF.
  • nitrate-nitrite reductase gene cluster of Penicillium chrysogenum Cloning of the nitrate-nitrite reductase gene cluster of Penicillium chrysogenum and use of the niaD gene as a homologous selection marker. J Biotechnol. 1991 Sep;20(2): 189-99).
  • the niaD gene enables direct selection of transformants on plates containing chlorate, as cells become resistant to chlorate.
  • the sutB gene has already been described elsewhere (van de Kamp M, Pizzinini E, Vos A, van der Lende TR, Schuurs TA, Newbert RW, Turner G, Konings WN, Driessen AJ. Sulfate transport in Penicillium chrysogenum: cloning and characterization of the sutA and sutB genes.
  • a preferred selection marker gene is the A.nidulans amdS coding sequence fused to the A.nidulans gpdA promoter (EP635 574 B). AmdS genes from other filamentous fungi may also be used (WO 97/06261). In the preferred form of the phenotypic screen, the amdS gene is present at the predetermined genomic site and the ble gene is used as the gene to be targeted to the predetermined site.
  • mutants with improved HR there will be a limited number of transformants on the acetamide— phleomcycin double selective plates as the amdS- cassette is efficiently exchanged with the We-cassette. In this case more mutants will appear on fluoracetamide-phleomycin double selective plates.
  • the filamentous fungus having a lowered NHR efficiency and/or a decreased NHR/HR ratio is a filamentous fungus wherein a component involved in NHR has been inhibited.
  • a means "at least one”: at least one component involved in NHR has been inhibited in a given filamentous fungus.
  • Inhibition can be achiev&d by down regulating the expression level of a gene involved in NHR or inactivating a gene encoding a component involved in NHR and/or by down regulating the expression level of a component involved in NHR, and/or (temporarily) decreasing the (protein) activity of a component involved in NHR and a combination of these possibilities.
  • the filamentous fungus obtained has the expression of a gene involved in NHR down regulated by comparison to the expression of said gene in the parent filamentous fungal cell it originates from under the same conditions.
  • tie parent filamentous fungus is one of the filamentous fungus as defined under the section host cell.
  • the expression level of a gene, or a DNA sequence is down regulated when the expression level of this specific gene or DNA sequence in the obtained filamentous fungus is lower than the expression level of the same gene or DNA sequence in the parental filamentous fungus it originates from, preferably three times lower, more preferably four times lower, most preferably more than four times lower and even most preferably not detectable using northern, or western blotting or 'omics' techniques like transcriptomics and proteomics.
  • the down and/or up regulation of the expression level of a DNA sequence can be monitored by quantifying the amount of corresponding mRNA present in a cell by northern blotting (in Molecular Cloning: A Laboratory Manual, Sambrook et al., New York: Cold Spring Harbour Press, 1989) for example and/or by quantifying the amount of corresponding protein present in a cell by western blotting for example.
  • the difference in mRNA amount may also be quantified by DNA array analysis (Eisen, M.B. and Brown, P.O. DNA arrays for analysis of gene expression. Methods Enzymol. 1999:303:179- 205).
  • the down regulation of the expression level of at least one gene or DNA sequence may be obtained by genetic manipulation by one of the following techniques or by a combination thereof: a. using recombinant genetic manipulation techniques, b. submitting the filamentous fungus to mutagenesis.
  • the down regulation of the expression level of at least one gene or DNA sequence may be obtained by submitting the filamentous fungus to a inhibiting compound/composition.
  • the filamentous fungus obtained may be subsequently selected by monitoring the expression level of said gene or DNA sequence.
  • the filamentous fungus is subsequently selected by measuring its efficiency of the NHR and/or of the HR pathways and/or its NHR/HR ratio.
  • the efficiency of the HR pathway of a filamentous fungus may be measured by the efficiency of the targeted integration of a given poynucleotide sequence into a predetermined site in the genome of the filamentous fungus using given homology region(s).
  • the efficiency of the NHR pathway of a filamentous fungus may be measured by the efficiency of the non targeted integration of a given polynucleotide sequence in the genome of the filamentous fungus irrespective of any homology region(s).
  • the down regulation of the expression of st least one DNA sequence is made with recombinant genetic manipulation techniques such as defined in step a. to obtain a recombinant filamentous fungus. Most preferably step a.
  • an appropriate DNA sequence has to be introduced at the target locus.
  • the target locus is in this case the DNA sequence involved in NHR pathway to be deleted or replaced.
  • the appropriate DNA sequence is preferably present on a cloning vector. Suitable cloning vector are the ones that are able to integrate at the predetermined target locus in the chromosomes of the filamentous fungal host cell used.
  • Preferred integrative cloning vector comprises a DNA fragment, which is homologous to the DNA sequence to be deleted or replaced for targetjngi the integration of the cloning vector to this pre-determined locus.
  • the cloning vector is preferably linearized prior to transformation of the host cell. Preferably, linearization is performed such that at least one but preferably either end of the cloning vector is flanked by sequences homologous to the DNA sequence to be deleted or replaced.
  • the length of the homologous sequences flanking the DMA sequence to be deleted or replaced is preferably less than 2 kb, even prefenafe ⁇ l ⁇ _ less than 1 kb, even more preferably less than O. ⁇ kb, even more preferably Jess than 0.2kb, even more preferably less than 0.1 kb, even more preferably less than 50bp and most preferably less than 30bp.
  • the selection marker gene in the cloning vector can be selected from a number of marker genes that are useful for transformation of filamentous fungi.
  • these markers include but are not limited to dominant and bi-directional selection marker gene such as an acetamidase (amdS) gene (EP 635 574 B or WO 97/06261), auxotrophic marker genes such as argB, trpC, or pyrG and antibiotic resistance genes providing resistance against e.g. phleomycin, hygromycin B or G418.
  • a preferred selection marker gene is the A.nidulans amdS coding sequence fused to the A.nidulans gpdA promoter (EP635 574 B). AmdS genes from other filamentous fungus may also be used (WO 97/06261).
  • the amdS selection marker gene has the advantage it can be used several times in the same strain to replace and/or delete distinct DNA sequences. By means of counterselection on fluoracetamide media as described in EP 635 574 B, the resulting strain is marker free and can be used for further gene modifications.
  • a preferred strategy for down regulating the expression of a given DNA sequence comprises the deletion of the wild type DNA sequence and/or replacement by a modified DNA sequence, whose expression product is not functional.
  • the deletion and the replacement are preferably performed by the gene replacement technique described in EP 0 357 127 BL
  • the specific deletion of a gene is preferably performed using the amdS gene as selection marker gene as described in EP 635574 B.
  • a tectinique based on in vivo recombination of cosmids in E. coli can be used, as described in: A rapid method for efficient gene replacement in the filamentous fungus AspergillLrs nidulans (2000) Chaveroche, MK., Ghico, J-M. and d'Enfert C; Nucleic adds Research, vol 28, no 22. This technique is applicable to other filamentous fungi like for example A niger.
  • Down regulating the expression of a DNA sequence may also be achieved by using anti sense nucleic acids, or by UV or chemical mutagenesis (Mattern, I.E., van Noort J.M., van den Berg, P., Archer, D. B., Roberts, LN. and van den Hondel, C A., Isolation and characterization of mutants of Aspergillus niger deficient in extracellular proteases. Mol Gen Genet. 1992 Aug;234(2):332-6.).
  • the deficiency brought in the NHR pathway is an inducible one.
  • This can be reached by replacing the endogenous regulatory egions of the gene encoding the component involved in NHR by new regulatory regions, preferably by using a repressible or regulatable promoter, more preferably by using a promoter that can be switch on/off: by glucose repression, or ammonia repression, or pH repression.
  • glucose- repressed promoters are the Penicillium chrysogenum pcbAB promoter (Martin JF, Casqueiro J, Kosalkova K, Marcos AT, Gutierrez S. Penicillin and cephalosporin biosynthesis: mechanism of carbon catabolite regulation of penicillin production.
  • the filamentous fungus is deficient in at least one of its endogenous genes, which are homologous with the following yeast genes involved in the NHR pathway KU70, KU80, RAD50, MRE11, XRS2 and SIR4 (van den Bosch ot al (2002): DNA double-strand break repair by homologous recombination. Biol. Chern. Vol.383:873-892 and Allen et al, (2003): Interactive competition between homologous recombination and non-homologous end joining. Mol. Cancer Res., vol 1:913-920).
  • mutants having at least one component involved in NHR which is no longer capable or at least significantly less capable to perform its function in the process of NHR, are mutants contemplated by the present invention.
  • the component involved in NHR has been hhibited so that the efficiency of the NHR pathway in trie obtained mutant is less than 90% of the activity in the parent cell it originates from under the same conditions as measured in the assay defined earlier, even preferably less than 85%, more preferably less than 80%, even more preferably less than 70%, most preferably less than 50%.
  • the parent filamentous fungus is one of filamentous fungus as defined under the section host cell.
  • the filamentous fungus cell is deficient in at least one of the following genes z
  • the filamentous fungus has the amount of at least one of the proteins encoded by these genes ⁇ df.4 and hdfB that is decreased upon induction.
  • the down regulation of the expression level of at least one gene or DNA sequence may be obtained by genetic modification by submitting the filamentous fungus to mutagenesis.
  • Filamentous fungal cells may be subjected to random mutagenesis and subsequently to a selection assay to isolate trie mutants with improved HR from the whole diverse population of mutants.
  • one of the filamentous fungal cell defined under the sedion host cell is used as starting strain to perform the mutagenesis.
  • the starting strain is subjected to UV irradiation so that the survival percentage is ranged between 0.001% and 60%.
  • the survival percentage is ranged between 0.01% and 50%.
  • conidiospores is the preferred material to mutagenize filamentous fungi by physical or chemical means. Mutants may however also be obtained from mycelium cells. Also, other mutagenic treatments than UV can be applied as chemical agents (e.g. NTG). The seledion method described herein may be applied to select mutants obtained from either conidiospores or mycelium cells.
  • the mutagenesis is applied to conidiospores.
  • UV irradiation is preferably applied for different times such as 7.5, 15 and 30 minutes to obtain mild, medium and strong mutation rate levels in the cells.
  • the mutated samples may either be directly re- sporulated or incubated for an extended recovery period in a rich medium such as YNF3 or YEPD (see definition in example. 9) before sporulation was induced (for example as described in example 9).
  • Protoplasts may be transformed with at least one, preferably two or more DNA fragments carrying expression cassettes rf functional selection markers.
  • the selection marker genes in the expression cassettes can bo seleded from a number of marker genes that are useful for transformation of filamentou s fungi.
  • these markers indude but are not limited to dominant and bi - directional selection marker gene such as an acetamidase (amdS) gene (EP 635574 F3 or WO 97/06261), auxofrophic marker genes such as argB, trpC, or pyrG and antibiotic resistance genes providing resistance against e.g.
  • the seledion markers used are the ble and amdS genes.
  • the amdS cassette used is the A.nidulans coding sequence fused to the A.nidulans gpdA promoter (EP635 574 B).
  • amdS genes from other filamentous fungus may also be used (WO 97/06261)-.
  • the gene bb encodes a protein capable of conferring resistance to phleomycin.
  • the gene amdS encodes a protein enabling cells to grow on acetamide as the sole nitrogen source (as described in EP635 574B).
  • the homologous stretches of DNA could typically vary from 30bp to 1000bp, preferably 30bp to 700bp, more preferably 30bp to 500bp, even more preferably 30bp to 300bp, more preferably preferably 30bp to 200bp, even more preferably 30bp to 100 bp and most preferably 30bp.
  • all loci in the filamentous fungi genome could be chosen for targeting integration of the expression cassettes.
  • the locus wherein targeting will take place is such that when the wild type gene present at this locus has been replaced by the gene comprised in the expression cassette, the obtained mutant will display a change detedable by a given assay.
  • the locus is the niaD locus, thereby disrupting the nitrate reductase gene (Gouka RJ, van Hartingsveldt W, Bovenberg RA, van den Hondel CA, van Gorcom RF. Cloning of the nitrate-nitrite reductase gene duster of Penicillium chrysogenum and use of the niaD gene as a homologous selection marker. J Biotechnol. 1991 Sep;20(2): 189-99), enabling direct selection of transformants on plates containing chlorate, as cells become resistant to chlorate.
  • Another preferred locus is the sutB locus, thereby disrupting the sulphate permease gene (van de Kamp M, Pizzinhi E, Vos A, van der Lende TR, Schuurs TA, Newbert RW, Turner G, Konings WN, Driessen AJ. Sulfate transport in Penicillium chrysogenum: cloning and charaderization of the sutA and sutB genes. J. Bacteriol. 1999 Dec;181(23):7228-34), enabling dired selecfon of transformants on plates containing selenate. Mutants with both selection markers present and having the two alterations resulting from the inadivation of the genes present at the integration lod are strains with improved targeted integration.
  • the mutant filamentous fungus having a lowered efficiency in the NHR pathway, or a decreased NHR/HR ratio and/or an elevated efficiency of the HR pathway is obtained by decreasing, more preferably partially or most preferably completely inhibiting a component involved in NHR.
  • Partial or complete inhibition of a component involved in NHR can be obtained by different methods, for example by an antibody directed against such a component or a chemical inhibitor or a protein inhibitor or a physical inhibitor (Tour O. et al, (2003) Nat. Biotech: Genetically targeted chromophore-assisted light inactivation. Vol.21. no. 12:1505-1508) or peptide inhibitor or an anti-sense molecule or RNAi molecule (R.S.
  • Components involved in NHR comprise filamentous fungal homologues of yeast KU70, RAD50, MREII, XRS2, LIG4, SIR4, KU80, LIFL or NEIL or associating component.
  • the nomenclature of genes differs between organisms a functional equivalent or a functional and/or a functional fragment thereof, all defined herein as being capable of performing (in fundion, not in amount) at least one function of the yeast genes KU70, RAD50, MREII, XRS2, LIG4, SIR4, KU80, LIFL or NEIL are also induded in the present invention.
  • a nudeic acid is integrated at any desired position without permanently modifying a component involved in NHR and preventing unwanted side effects caused by the permanent presence of such a modified component involved in NHR.
  • the Aspergillus nidulans carnitine carrier encoded by the acuH gene is exclusively located in the mitochondria. FEMS Microbiol Lett. 2001 Jul 24;201(2):193-8.) or retention signals (Derkx, P. M. andMadrid, S. M. The foldase CYPB is a component of the secretory pathway of Aspergillus niger and contains the endoplasmic reticulum retention signal HEEL. Mol. Genet. Genomics.2001 Dec;266(4):537-45.).
  • inhibition of protein activity can also be obtained by UV or chemical mutagenesis (Mattern, I.E., van Noort J.M., van den Berg, P., Archer, D. B., Roberts, l.N. and van den Hondel, C. A., Isolation and characterization of mutants of Aspergillus niger deficient in extracellular proteases. Md Gen Genet. 1992 Aug;234(2):332-6.) cr by the use of inhibitors like the proteasomal inhibitor of Affinity (clasto-ladacystin- ⁇ -lactone, Affinity Research Products Ltd., CW8405-Z02185.).
  • the steering towards HR comprises adding an excess of small double stranded polynucleotides able to bind and thereby limit the expression of NHR components, next to the polynudeotide to be integrated (Agrawal N. et al,: RNA interference: biology, mechanism and applications. Microbiol. Mol. Biol. Rev., vol. 67, no. 4:657-685).
  • the invention provides a method for increasing the efficiency of targeted integration of a polynudeotide to a pre-determined site, whereby said polynucleotide has homology at or around the said pre-determined site, in a filamentous fungus with a preference for NHR comprising steering an integration pathway towards HR by providing a filamentous fungal cell, wherein the effidency of the HR pathway has been elevated compared to the one of the parent filamentous fungus it originates from under the same conditions.
  • the efficiency of the HR pathway is preferably assayed by the same assay as the one used for determining the NHR HR ratio.
  • the parent organism is one of the filamentous fungi as defined in the section host cell.
  • Elevated means at least higher than in the parental cell the obtained cell originates from.
  • elevated means twice higher, more preferably three times higher, even more preferably four times higher, most preferably more than four times higher using northern, or western blotting or array technique or a phenotypic screen.
  • the filamentous fungus has the expression level of at least one gene involved in HR, which has been up regulated by comparison to the expression level of the same gene in the filamentous fungal cell it originates from.
  • This can be achieved by increasing the expression level of a gene encoding a component involved in HR and/or by increasing the expression level of a component involved in HR and/or by (temporarily) increasing the activity of the component involved in HR.
  • the filamentous fungus obtained has the expression of a gene involved in HR, which has been up regulated by comparison to the expression of said gene in the filamentous fungal cell it originates from.
  • the expression level of a DNA sequence is up regulated when the expression level of this specific DNA sequence in the obtained filamentous fUngus is higher than the expression level of the same DNA sequence in the parental filamentous fungus it originates from , preferably three times higher, more preferably four times higher, most preferably more than four times higher using northern, or western blotting or array technique.
  • the parent organism is one of the filamentous fungi as defined in the section host cell.
  • the up regulation of the expression level of at least one DNA sequence may be obtained by genetic manipulation by one of the following techniques or by a combination thereof: c. using recombinant genetic manipulation techniques, d. submitting the filamentous fUngus to mutagenesis,
  • the up regulation of the expression level of at least one gene or DNA sequence may be obtained by submitting the filamentous fungus to an activating compound/composition.
  • the filamentous fungus may be subsequently selected by monitoring the expression level of said DNA sequence and optionally the efficiency of the HR pathway of the filamentous fungus.
  • the HR efficiency of a filamentous fungus may be measured by the effidency of the targeted integration of a given polynucleotide sequence into a pre- determined site in the genome of the filamentous fungus using given homology region(s).
  • the up regulation of the expression of at least one DNA sequence is made with recombinant genetic manipulation techniques such as defined in step a. to obtain a recombinant filamentous fungus.
  • step a. comprises transforming the filamentous fungus with a DNA construd comprising the DNA sequence, preferably said DNA sequence being operationally linked to a promoter of a highly expressed gene.
  • the chosen promoter may be stronger than the endogenous promoter of the DNA sequence to be over expressed.
  • the promoter for expression of the DNA sequence is preferably derived from a highly expressed fungal gene.
  • a number of preferred highly expressed fungal genes are given by way of example: the amylase, glucoamylase, alcohol dehydrogenase, xylanase, glyceraldehyde-phosphate dehydrogenase or cellobiohydrolase genes from Aspergilli or Trichoderma
  • Most preferred highly expressed genes for these purposes are an Aspergillus niger glucoamylase gene, an Aspergillus oryzae TAKA-amylase gene, an Aspergillus nidulans gpdA gene or a Trichoderma reesei cellobiohydrolase gene.
  • a glucoamylase promoter is the most preferred promoter to be used.
  • step a. comprises increasing the copy number of the DNA sequence into the filamentous fungal cell, preferably by integrating into its genome copies of the DNA sequence, more preferably by targeting the integration of the DNA sequence at a highly expressed locus, preferably at a glucoamylase locus.
  • the up regulation of the expression of the DNA sequence may be reached by increasing the copy number of the DNA sequence by introducing at least one copy of the DNA sequence into the filamentous fungus or by changing for a stronger promoter or changing for a gene encoding a protein with better kinetics and/or lifetime.
  • the DNA sequence may be present on a plasmid or integrated into the genome.
  • the skilled person can choose amongst two alternative possibilities: - over express at least one endogenous DNA sequence of the filamentous fungus being involved in the HR pathway.
  • the filamentous fungus comprises several copies of its endogenous DNA sequence.
  • the filamentous fungus would have its endogenous DNA sequence involved in HR and, in addition at least one copy of a heterologous DNA sequence involved in HR.
  • This heterologous DNA sequence is an homologue of its corresponding endogenous DNA sequence.
  • the filamentous fungus can be transformed with one or more copy of the DNA sequence (derived from inter alia Tilbum et al, 1983, Gene, 26:205-221).
  • the DNA sequence can be either stably integrated into the genome of the filamentous fungus or introduced into the cell as part of a DNA molecule capable of autonomous replication
  • the DNA sequence is preferably present on a doning vedor. Any cloning vector capable of transforming a filamentous fungal host cell is suitable for use in the present invention.
  • Cloning vectors for use in the invention thus comprise integrative cloning vectors, which integrate at random or at a predetermined target locus in the chromosomes of the filamentous fungal host cell, as well as autonomously maintained doning vectors such as vectors comprising the AMA1-sequence
  • the integrative doning vector comprises a DNA fragment, which is homologous to a DNA sequence in a predetermined target locus in the genome of the filamentous fungal host cell for targeting the integration of the cloning vector to this predetermined locus.
  • the cloning vector is preferably linearized prior to transformation of the host cell.
  • Linearization is preferably performed such that at least one but preferably either end of the doning vector is flanked by sequences homologous to the target locus.
  • the length of the homologous sequences flanking the target locus is preferably at least 30bp, preferably at least 50 bp, preferably at least 0.1kb, even preferably at least 0.2kb, more preferably at least 0.5 kb, even more preferably at least 1 kb, most preferably at least 2 kb.
  • the DNA sequence in the doning vector, which is homologous to the target locus is derived from a highly expressed locus meaning that it is derived from a gene, which is capable of high expression level in the filamentous fungal host cell.
  • a gene capable of high expression level i.e. a highly expressed gene, is herein defined as a gene whose mRNA can make up at least 0.5% (w/w) of the total cellular mRNA, e.g.
  • the technique of gene conversion as described in W098/46772 may be used.
  • the skilled person will appreciate the possibility that the homologous DNA sequence for targeting and the promoter sequence can coincide in one DNA fragment.
  • the list of highly expressed genes given above is also suited as target locus.
  • an autonomously maintained cloning vector is a cloning vedor comprising the AMA1 -sequence.
  • AMA1 is a 6.0-kb genomic DNA fragment isolated from Aspergillus nidulans, which is capable of Autonomous Maintenance in Aspergillus (see e.g. Aleksenko and Clutterbuck (1997), Fungal Genet. Biol.21: 373-397).
  • step a. comprises transforming the filamentous fungus with a DNA construct comprising a selection marker gene.
  • the selection marker gene in the cloning vector can be selected from a number of marker genes that are useful for transformation of filamentous fungi.
  • these markers include but are not limited to dominant and bi- diredional seledion marker genes such as an amdS gene (EP 635574, WO 97/06261), auxotrophic marker genes such as argB, trpC, or pyrG and antibiotic resistance genes providing resistance against e.g. phleomycin, hygromycin B or G418.
  • an amdS gene is preferred, more preferably an amdS gene from Aspergillus nidulans or Aspergillus niger.
  • a most preferred selection marker gene is VheA.nidulans amdS coding sequence fused to the A.nidulans gpdA promoter (see EP635574). AmdS genes from other filamentous fungus may also be used (WO 97/06261). The amdS seledion marker gene has the advantage it can be used several times in the same strain to introduce, over express and/or delete distinct DNA sequences. By means of counterseledion on fluoracetamide media as described in EP 635574, the resulting strain is marker free and can be used for further gene modifications.
  • up regulation of the expression of a DNA sequence can be reached using UV or chemical mutagenesis (Mattern, I.E., van Noort J.M., van den Berg, P., Archer, D. B., Roberts, LN. and van den Hondel, C. A., Isolation and characterization of mutants of Aspergillus niger deficient in extracellular proteases. Mol Gen Genet 1992 Aug;234(2):332-6.).
  • each of the described technique may be used either separately or in combination.
  • the skilled person would also understand that to obtain a filamentous fungus with an increased HR/NHR ratio, and/or with a lowered NHR dficiency and/or an elevated HR efficiency, one may use at least one of each technique described for respectively down and up regulating the expression of a given gene in a filamentous fungus.
  • all the techniques performed on the filamentous fungus to obtain a recombinant filamentous fungus having both a lowered NHR efficiency and an elevated HR efficiency have been performed using a dominant and bi-directional selection marker, preferably an amdS gene more preferably an amdS gene from Aspergillus nidulans or Aspergillus niger.
  • the obtained filamentous fungus may be subsequently selected by monitoring the expression level of said DNA sequence as described before by using for example northern and/or western blotting and/or array and/or phenotype screening.
  • the efficiency of the NHR and/or HR pathways of the cell is monitored. The efficiency of these pathways of a filamentous fungus may be monitored as defined earlier on.
  • the modification brought in the HR pathway is an indudble one.
  • This can be reached by replacing the endogenous regulatory regions of the gene encoding the component involved in HR by indudble regulatory regions, preferably by using an indudble promoter.
  • indudble promoters are the glucoamylase promoter of Aspergillus niger, the TAKA amylase promoter of Aspergillus oryzae, the paf promoter (Marx,F., Haas.H., Reindl.M., Stoffier.G., Lottspeich.F. and Redl.B.
  • Penicillium chrysogenum paf gene encoding an abundantly secreted protein with antifungal activity Gene 167 (1-2), 167- 171 (1995) or the pcbC promoter of Penicillium chrysogenum (Martin JF, Casqueiro J, Kosalkova K, Marcos AT, Gutierrez S. Penicillin and cephalosporin biosynthesis: mechanism of carbon catabolite regulation of penicillin production. Antonie Van Leeuwenhoek. 1999 Jan-Feb;75(1-2):21-31. Review. ) or the switch on/off systems earlier cited for down regulation of the expression of genes involved in NHR.
  • the genes involved in the HR pathway which are modified are the following genes or homologues thereof: RAD51 , RAD52.
  • mutants having at least one component involved in HR which is more capable or at least significantly more capable to perform its function in the process of HR are mutants contemplated by the present invention.
  • the activity of the components involved in HR has been modified so that the efficiency of the HR pathway is more than 110% of the efficiency in the parent cell it originates from under the same conditions as measured in the assay defined earlier, more preferably more than 200%, most preferably more than 500%.
  • the parent organism is one of the filamentous fungi as defined under the sedion host cell.
  • the present invention further relates to the filamentous fungus per se, which is preferably used in the method of the invention for increasing the efficiency of targeted integration of a polynucleotide to a pre-determined site into the genome of said filamentous fungal cell, said filamentous fungus having a preference for NHR, and wherein said polynucleotide has a region of homology with said pre-determined site and said method comprising steering an integration pathway towards HR.
  • the charaderistjcs of the filamentous fungus that can be used in this method have been earlier defined.
  • the filamentous fungus preferably used in the method of the invention is a mutant originating from a parent cell, wherein the ratio of NHR/HR is decreased and/or wherein the efficiency of the NHR pathway has been lowered and/or the effidency of the HR pathway has been elevated in said mutant cell as compared to said ratio and said effidencies in said parent organism under the same conditions.
  • the assay used to determine the ratio NHR/HR and/or the efficiency of the NHR pathway and/or the effidency of the HR pathway has been earlier described .
  • the host cell of the present invention is a filamentous fungus, which is capable of being transformed with a cloning vector.
  • filamentous fungi tested thus far it was found that they could be transformed using transformation protocols developed for Aspergillus (derived from inter alia Tilbum et al. 1983, Gene 26. :205-221).
  • transformation protocols developed for Aspergillus derived from inter alia Tilbum et al. 1983, Gene 26. :205-221).
  • successful transformation of the filamentous fungal host species is not limited to the use of vectors, selection marker systems, promoters and transformation protocols specifically exemplified herein.
  • a filamentous fungus is herein defined as a eukaryotic microorganism of the subdivision Eumycotina in filamentous form, i.e. the vegetative growth of which occurs by hyphal elongation.
  • Preferred filamentous fungal host cells are selected from the group consisting of the genera Aspergillus, Trichoderma, Fusarium, Penicillium, and Acremonium.
  • the filamentous fungal host cell is seleded from the group consisting of Anidulans, A.oryzae, A.sojae, Aspergilli of the A.niger Group, Trichoderma reesei and Penicillium species.
  • the Penicillium is a Penicillium chrysogenum or Penicillium citrinum spedes.
  • the A.niger group is herein defined according to Raper and Fennell (1965, In: The Genus Aspergillus, The Williams & Wilkins Company, Baltimore, pp 293-344) and comprises all (black) Aspergilli therein included by these authors.
  • Most preferred filamentous fungal host cells are selected from the group consisting of Aspergilli of the A.niger group, A.oryzae, Trichoderma reesei and Penicillium chrysogenum.
  • the parent organism is the deposited filamentous fungus cell Aspergillus niger CBS 513.88, Aspergillus oryzae ATCC 20423, IFO 4177, ATCC 1011, ATCC 9576, ATCC14488-14491, ATCC 11601, ATCC12892, Penicillium chrysogenum CBS -455.95 or or Penicillium citrinum ATCC 38065, Penicillium chrysogenum P2, Acnemonium chrysogenum ATCC 36225 or ATCC 48272, Trichoderma reesei ATCC 26921 or ATCC 56765 or ATCC 26921, Aspergillus sojae ATCC11906, Chrysosporium lucknowense ATCC44006, Claviceps paspali CBS110.22, Claviceps pu ⁇ urea CBS164.59, Penicillium brevicompactum ATCC 9056, Aspergillus terreus ATCC 20542,
  • the filamentous fungal cell of the invention has a ratio NHR/HR, which is at least 200, at least 50, at least 10 as measured by the following assay.
  • the ratio of the filamentous fungal cell is at least 1, more preferably at least 0.5, even more preferably at least 0.1, even more preferably at least 0.05, even more preferably at least 0.01 even more preferably at least 0.005 even more preferably at least 0.0O1 even more preferably at least 0.0005 even more preferably at least 0.0001 and most preferably at least 0.00001.
  • the filamentous fungal cell of the invention has a ratio NHR/HR, which is less than 200, even more preferably less than 50, less than 10 as measured by the following assay. Even more preferably the ratio of the filamentous fungal cell is less than 1 , even more preferably less than 0.5, even more preferably less than 0.1 , even more preferably less than 0.05, even more preferably less than 0.01 even more preferably less than 0.005 even more preferably less than 0.001 even more preferably less than O.0005 even more preferably less than 0.0001 and most preferably less than 0.00001.
  • the ratio of NHR HR is preferably measured by the assay as described in WO 02/052026 (table 2, p23).
  • the filamentous fUngal cell is deficient in a gene encoding a component involved in NHR, and/or has a decreased level of a component involved in NHR.
  • the filamentous fungal cell is deficient in at least one of the following genes: hdfA or homologues thereof as identified in SEQ ID NO: 2 or 19, hdfB or homologues thereof as identified in SEQ ID NO: 5, or 22 or both, and/or has, preferably a decreased amount of at least one of the proteins encoded by these genes.
  • the filamentous fungal cell is inducibly deficient at least one of the following genes: hdfA or homologues thereof as identified in SEQ ID NO: 2 or 19, hdfB or homologues thereof as identified in SEQ ID NO: 5, or 22 or both, and/or has, preferably inducibly, a decreased amount of at least one of the proteins encoded by these genes.
  • the filamentous fungal cell is such that in its genome, a gene involved in NHR has been replaced by a non-functional gene or by a selection marker or by another gene.
  • the mutant has an increased level of a component involved in HR.
  • the filamentous fungus according to the invention may have been obtained by molecular biology techniques.
  • a filamentous fungus obtained by such a genetic engineering approach is defined as a recombinant filamentous fungus.
  • a recombinant filamentous fungus in the context of the invention could have been subjected earlier in time to mutagenesis technique to reach another wanted effect.
  • the filamentous fungus obtained is a recombinant filamentous fungus.
  • a method which comprises at least the steps of introducing a polynucleotide of interest into the filamentous fungus of the invention, for example by the process of transformation or electroporation, and integration of said polynucleotide in the genetic material of said cell.
  • Integration is a complex process wherein a nucleic acid sequence becomes part of the genetic material of a host cell.
  • One step in the process of nudeic add integration is recombination; via recombination nucleic add sequences are exchanged or inserted and the introduced nucleic acid becomes part of the genetic material of a host cell.
  • two different ways of recombination are possible: homologous and illegitimate or NHR.
  • the length of a (nearly) homologous region is approximately 3 kb which is sufficient to direct homologous recombination. At least one homologous region is necessary for recombination but more preferably two homologous regions flanking the nudeic acid of interest are used for targeted integration. The researcher skilled in the art knows how to select the proper percentage of homology, the length of homology and the amount of homologous regions.
  • nucleic acid is integrated at every desired position within the genetic material of a host cell.
  • the invention as disclosed herein is used to direct any nucleic acid (preferably DNA) to any pre-determined site as long as the length of homology and percentage of homology are high enough to provide/enable HR.
  • a polynucleotide could not have always easily been integrated at every desired position into the genome of a given filamentous fungus.
  • the method according to the invention is applied, for example, to affect the gene function in various ways, not only for complete inactivation but also to mediate changes in Hie expression level or in the regulation of expression, changes in protein activity or the subcellular targeting of an encoded protein.
  • Complete inactivation is also useful to reduce the production of toxic or unwanted compounds (chrysogenin in Penicillium; Aflatoxin in Aspergillus: MacDonald KD et al,: heterokaryon studies and the genetic control of penicillin and chrysogenin production in Penicillium chrysogenum. J Gen Microbiol. (1963) 33:375-83). Complete inactivation is also useful to alter the morphology of the organism in such a way that the fermentation process and down stream processing is improved.
  • the invention allows to replace existing regulatory sequences by alternative regulatory sequences to alter expression of endogenous genes (e. g. expression in response to specific inducers.
  • One aspect of the present invention relates to the replacement of an active gene by an inactive gene according to a method of the invention.
  • Complete inactivation which can usually not be accomplished by existing methods such as antisense technology or RNAi technology, is useful for instance for the inactivation of genes controlling undesired side branches of metabolic pathways, for instance to increase the quality of bulk products such as starch, or to increase the produdion of specific secondary metabolites or to inh ⁇ bit formation of unwanted metabolites.
  • Another aspect of the invention relates to the extensive metabolic reprogramming or engineering of a filamentous fUngal cell. Introdudiori of complete new pathways and/or modification of unwanted pathways will lead to the obtention of a cell specifically adapted for the produdion of a specific compound such as a protein or a metabolite.
  • Another aspect of the present invention relates to the replacement of an inactive or altered gene by an adive gene. For example, after successive rounds of classical mutagenesis, it often occurs the selected filamentous fungal strain has some endogenous genes altered or even inactivated during the random mutagenesis process.
  • a method to introduce a substance conferring resistance for an antibiotic substance to a filamentous fungal cell in yet another aspect of the invention there is provided a method to confer a desired property to a filamentous fungal cell.
  • a gene delivery vehicle is used to deliver a desired polynucleotide to a predetermined site. Gene delivery vehides are well known in the art and have been earlier described in the description.
  • the filamentous fungus provided by the invention further comprises a DNA construct comprising a desired gene coding for a desired protein to be produced.
  • the desired gene encoding the desired protein to be produced is inserted into an expression vector, which is subsequentiy used to transform the obtained host cell.
  • the DNA sequence may be operationally linked to appropriate expression signals, such as a promoter, optionally a signal sequence and a terminator, which are capable of directing the expression and synthesis of the protein in the host organism.
  • the desired gene is operationally linked to a promoter and to a secretion signal.
  • the strategy, which can be used to express the desired gene is the same as the one described under the sedion up regulation of the expression of a DNA sequence, whose expression product is involved in HR: increasing copy number, targeting integration, use of a promoter of a highly expressed gene, choice of the selection marker gene and combinations thereof.
  • the desired protein is preferably an enzyme. If the protein is not naturally secreted, the polynuclelotide encoding the protein may be modified to have a signal sequence in accordance with techniques known in the art.
  • the proteins, which are secreted may be endogenous proteins which are expressed naturally, but can also be heterologous.
  • Heterologous means that the gene encoded by the protein is not produced under native condition in the wild type filamentous fungus.
  • enzymes which may be produced by the filamentous fungi of the invention are carbohydrases, e.g. cellulases such as en oglucanases, ⁇ -glucanases, cellobiohydrolases or ⁇ -glucosidases, hemicellulases or pectinolytic enzymes such as xylanases, xylosidases, mannanases, galadanases, galactosidases, rhamnogaladuronases, arabanases, galacturonases, lyases, or amylolytic enzymes; phosphatases such as phytases, esterases such as lipases, proteolytic enzymes, oxidoreductases such as oxidases, transferases, or isomerases. More preferably, the desired gene encode
  • the protein encoded has optimized charaderistics for instance to make a protein with improved thermal charaderistics and/or improved kinetic properties (Km, Kcat), and/or improved enzyme stability, and/or extended substrate range, and/or increased life span, etc.
  • the invention further relates to the use of the filamentous fungus of the invention for producing a polypeptide of interest.
  • the filamentous fungus obtained may be used for produdng a secondary metabolite.
  • Preferred secondary metabolites are carotenoid compounds, beta-lactam compounds, drugs, anti-tumor co pounds, etc.
  • the filamentous fungus as obtained in the present invention is used for producing the desired protein by culturing the transformed host cell under conditions condudve to the expression of the DNA sequence encoding the desired protein, and recovering the desired protein as described forexample in the following references: - Li, Z. J., Shukla, V., Fordyce, A. P., Pedersen, A. G., Wenger, K. S., Marten, M. R. Fungal morphology and fragmentation behavior in a fed-batch Aspergillus oryzae fermentation at the production scale. Biotechnol Bioeng. 2000 Nov 5;70(3):300-12 Withers, J. M., Swift, R. J., Wiebe, M. G., Robson, G.
  • SEQ ID NO: 22 hdfB from Penicillium chrysogenum and homologues thereof.
  • Each SEQ ID NO: 1, 18, 4 and 21 corresponds respectively to the genomic DNA sequence associated with each cDNA sequence given above.
  • Each SEQ ID NO: 3, 20, 6 and 23 corresponds respectively to the protein sequence encoded by the respective cDNA sequence given above.
  • sequence information as provided herein should not be so narrowly construed as to require inclusion of erroneously identified bases.
  • the spedfic sequences disclosed herein can be readily used to isolate the complete gene from filamentous fungi, in particular A niger or Penicillium chrysogenum which in turn can easily be subjected to further sequence analyses thereby identifying sequencing errors.
  • nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer and all arnino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nudeotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art.
  • a single insertion or deletion in a determined nucleotide sequence compared to the adual sequence will cause a frame shift in translation of the nucleotide sequence such that the predided amino acid sequence encoded by a determined nudeotide sequence will be completely different from the amino acid sequence adually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.
  • Homologous is below defined. Homologous can be understood as meaning derived from other filamentous fungus than Aspergillus niger or Penicillium chrysogenum. Full length DNA from other organisms can be obtained in a typical approach, using cDNA or genomic DNA libraries constructed from other organisms, e.g. filamentous fungi, in particular from the species Aspergillus or Penicillium by screening them.
  • paralogues of hdfA and/or hdfB n the context of the invention, paralogues means DNA sequences homologous to SEQ ID NO: 1 or SEQ D NO: 4 or SEQ ID NO: 18 or SEQ ID NO: 21 and derived from A niger or Penicillium chrysogenum respectively.
  • Aspergillus or Penicillium strains can be screened for homologous hdfA and/or hdfB polynucleotides by Northern blot analysis.
  • cDNA libraries can be constructed from RNA isolated from the appropriate strain, utilizing standard techniques well known to those of skill in the art.
  • a total genomic DNA library can be screened using a probe hybridisable to an hdfA and/or hdfB polynucleotide according to the invention.
  • Homologous gene sequences can be isolated, for example, by performing PCR using two degenerate oligonucleotide primer pools designed on the basis of nucleotide sequences as taught herein.
  • the template for the reaction can be cDNA obtained by reverse transcription of mRNA prepared from strains known or suspeded to express a polynucleotide according to the invention.
  • the PCR product can be subcloned and sequenced to ensure that the amplified sequences represent the sequences of a new hdfA and/or hdfB nucleic acid sequence, or a fundional equivalent thereof.
  • the PCR fragment can then be used to isolate a full-length cDNA clone by a variety of known methods.
  • the amplified fragment can be labeled and used to screen a bacteriophage or cosmid cDNA library.
  • the labeled fragment can be used to screen a genomic library.
  • RNA can be isolated, following standard procedures, from an appropriate cellular or tissue source.
  • a reverse transcription reaction can be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis.
  • RNA/DNA hybrid can then be "tailed" (e.g., with guanines) using a standard terminal transferase reaction, the hybrid can be digested with RNase H, and second strand synthesis can then be primed (e.g., with a poly-C primer).
  • second strand synthesis can then be primed (e.g., with a poly-C primer).
  • Functional equivalents and “fundional variants” are used interchangeably herein.
  • Functional equivalents of hdfA and/or hdfB DNA are isolated DNA fragments that encode a polypeptide that exhibits a particular function of the hdfA and/or hdfB.
  • a fundional equivalent of an hdfA and/or hdfB polypeptide according to the invention is a polypeptide that exhibits at least one fundion as part of the NHR complex. Functional equivalents therefore also encompass biologically active fragments.
  • Functional protein or polypeptide equivalents may contain only conservative substitutions of one or more amino adds of sequences having SEQ ID NO: 3 or 6 or 20 or 23 or substitutions, insertions or deletions of non-essential amino acids.
  • a non-essential amino add is a residue that can be altered in one of these sequences without substantially altering the biological function.
  • amino acid residues that are conserved among the hdfA and/or hdfB proteins of the present invention are predided to be particularly unamenable to alteration.
  • amino acids conserved among the hdfA and/or hdfB proteins according to the present invention are not likely to be amenable to alteration.
  • substitution is intended to mean that a substitution in which the amino acid residue is replaced with an amino acid residue having a similar side chain.
  • amino acids with basic side chains e.g.lysine, arginine and hystidine
  • acidic side chains e.g.
  • aspartic acid glutamic acid
  • uncharged polar side chains e.g., glycine, asparagines, glutamine, serine, threonine, tyrosine, cysteine
  • non-polar side chains e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan
  • beta-branched side chains e.g., threonine, valine, isoleucine
  • aromatic side chains e.g., tyrosine, phenylalanine tryptophan, histidine
  • nudeic acid equivalents may typically contain silent mutations or mutations that do not alter the biological function of encoded polypeptide. Accordingly, the invention provides nucleic acid molecules encoding hdfA and/or hdfB proteins that contain changes in amino acid residues that are not essential for a particular biological activity. Such hdfA and/or hdfB proteins differ in amino acid sequence from SEQ ID NO: 3 or 6, or 20 or 23 and yet retain at least one of their biological activities.
  • the isolated nudeic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises a substantially homologous amino acid sequence of at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino add sequence shown in SEQ ID NO 3 or 6 or 20 or 23.
  • the protein comprises a substantially homologous amino acid sequence of at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino add sequence shown in SEQ ID NO 3 or 6 or 20 or 23.
  • the first method relies on the process of evolution, in which mutations are either accepted or rejected by natural selection.
  • the second approach uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene and seleds or screens to identify sequences that maintain functionality.
  • proteins are surprisingly tolerant of amino acid substitutions.
  • the authors further indicate which changes are likely to be permissive at a certain position of the protein. Ror example, most buried amino acid residues require non-polar side chains, whereas few features of surface side chains are generally conserved. Other such phenotypically silent substitutions are described in Bowie et al. and the references cited therein.
  • An isolated nucleic acid molecule encoding an hdfA and/or hdfB protein homologous to the protein according to SEQ ID ND: 3 or 6 or 20 or 23 can be created b>y introdudng one or more nucleotide substitutions, additions or deletions into the coding nucleotide sequences according to SEQ ID NO: 2 or SEQ ID NO: 5, or SEQ ID NO: 19 or SEQ ID NO: 22 such that one or more amino acid substitutions, deletions or insertions are introduced into the encoded protein.
  • Such mutations may be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis.
  • orthologues also encompasses orthologues of the . niger hdfA and/or hdfB protein.
  • Orthologues of the A niger hdfA and/or hdfB protein are proteins that can be isolated from other strains or species and possess a similar or identical biological activity. Such orthologues can readily be identified as comprising an amino acid sequence that is substantially homologous to SEQ ID NO: 3 or 6 or 20 or 23.
  • “Homologous” can also be understood as meaning “substantially homologous”.
  • the term “substantially homologous” refers to a first amino add or nudeotide sequence which contains a sufficient or minimum number of identical or equivalent (e.g., with similar side chain) amino acids or nucleotides to a second amino acid or nucleotide sequence such that the first and the second amino acid or nucleotide sequences have a common domain.
  • amino acid or nucleotide sequences which contain a common domain having about 45%, preferably about 50%, preferably about 60%, preferably about 65%, more preferably about 70%, even more preferably aboit 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity or more are defined herein as sufficiently identical.
  • nucleic acids encoding other hdfA and/or hdfB family members that have a nucleotide sequence that differs from SEQ ID NO: 2 or 5 or 19 or 22, are within the scope of the invention.
  • nucleic acids encoding hdfA and/or hdfB proteins from different species which thus have a nucleotide sequence which differs from SEQ ID NO: 2 or 5 or 19 or 22.
  • Nucleic add molecules corresponding to variants e.g.
  • hdfA and/or hdfB DNA of the invention can be isolated based on their homology to the hdfA and/or hdfB nudeic acids disclosed herein using the cDNAs disclosed herein or a suitable fragment thereof, as a hybridisation probe according to standard hybridisation techniques preferably under highly stringent hybridisation conditions.
  • "Stringency" of hybridization readions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures.
  • Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting -temperature.
  • stringency of hybridization reactions see Ausubel et al, Current Protocols in Molecular Biology, Wiley Intersciencet Publishers, (1995).
  • “Stringent conditions” or “high stringency conditions”, as defined herein, may be identified by those that (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride / 0.0015 M sodium citrate / 0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1 % bovine serum albumin / 0.1 *% Ficdl / 0.1 % polyvinylpyrrolidone / 50mM sodium phosphate buffer at pH 6.5 with 750* mM sodium chloride, 75 mM sodium citrate at 42°C ; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1 % sodium pyrophosphate, 5 x Denhardfs solution, sonicated salmon sperm DNA (50 Rg/ml
  • Modely stringent conditions may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and indude the use of washing solution and hybridization conditions (e. g., temperature, ionic strength and % SDS) less stringent that those described above.
  • moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardfs solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50 C.
  • the skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate fadors such as probe length and the like, or by using an algorithm suitable for determining sequence similarity.
  • Homologous (similar or identical) sequences can also be determined by using a "sequence comparison algorithm". Optimal alignment of sequences for comparison can be conduded, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl.
  • HSPs high scoring sequence pairs
  • the BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment
  • the BLAST algorithm then performs a statistical analysis of the similarity between two sequences (see, e. g., Kariin & Altschul, Proc. Nat'l. Acad. Sd. USA 90: 5873-5787 (1993)).
  • One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P (N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.
  • an amino add sequence is considered similar to a protein such as a protease if the smallest sum probability in a comparison of the test amino acid sequence to a protein such as a protease amino acid sequence is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
  • the similarity is at least 40% homology to one of the DNA sequences having SEQ ID NO:2, 5, 19 and 22. More preferably the similarity is at least 50%, more preferably, at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90%.
  • allelic variants of the hdfA and/or hdfB sequence the skilled person will recognise that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO: 2 or 5 or 19 or 22, thereby leading to changes in the amino acid sequence of the hdfA and/or hdfB protein without substantially altering the function of the hdfA and/or hdfB protein.
  • deteriorated hdfA and/or hdfB proteins are provided.
  • Deteriorated hdfA and/or hdfB proteins are proteins, wherein at least one biological activity is decreased.
  • Such proteins may be obtained by randomly introducing mutations along all or part of the hdfA and/or hdfB coding sequence, such as by saturation mutagenesis, and the resulting mutants can be expressed recombinantly and screened for biological adivity.
  • the art provides for standard assays for measuring their enzymatic activity and thus deteriorated proteins may easily be seleded.
  • the assay is the one described earlier on (see for example WO02/052026 page 23 or the phenotypic screening assay).
  • the hdfA and/or hdfB protein has an amino acid sequence according to SEQ ID NO: 3 or 6 or 20 or 23.
  • the hdfA and/or hdfB polypeptide is substantially homologous to the amino add sequence according to SEQ ID NO: 3 or 6 or 20 or 23 and retains at least one biological adivity of a polypeptide according to SEQ ID NO:3 or 6 or 20 or 23, yet differs in amino acid sequence due to natural variation or mutagenesis as described above.
  • the hdfA and/or hdfB protein has an amino acid sequence encoded by an isolated nucleic acid fragment capable of hybridising to a nudeic acid according to SEQ ID NO: 2 or 5 or 19 ⁇ 22, preferably under highly stringent hybridisation conditions.
  • the hdfA and/or hdfB protein is a protein which comprises an amino acid sequence at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 3 or 6 or 20 or 23 and retains at least one fundional adivity of the polypeptide according to SEQ ID NO: 3 or 6 or 20 or 23.
  • Fundional equivalents of a protein according to the invention can also be identifed e.g. by screening combinatorial libraries of mutants, e.g. truncation mutants, of the protein of the invention for a given activity.
  • a variegated library of variants is generated by combinatorial mutagenesis at the nucleic add level.
  • a variegated library of variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential protein sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display).
  • libraries of fragments of the coding sequence of a polypeptide of the invention can be used to generate a variegated population of polypeptides for screening a subsequent selection of variants.
  • a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of the coding sequence of interest with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked produds, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vedor.
  • an expression library can be derived which encodes Nterminal and internal fragments of various sizes of the protein of interest
  • REM Recursive ensemble mutagenesis
  • Fragments of a polynucleotide according to the invention may also comprise polynucleotides not encoding fundional polypeptides. Such polynucleotides may function as probes or primers for a PCR reaction.
  • Nudeic adds according to the invention irrespective of whether they encode functional or non-functional polypeptides, can be used as hybridization probes or polymerase chain reaction (PCR) primers.
  • Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having an hdfA and/or hdfB adivity include, inter alia, (1) isolating the gene encoding the hdfA and/or hdfB protein, or allelic variants thereof from a cDNA library e.g. from other organisms than A niger or Penicillium chrysogenum; (2) in situ hybridization (e.g.
  • FISH FISH to metaphase chromosomal spreads to provide precise chromosomal location of the hdfA and/or hdfB gene as described in Verma et al., Human Chromosomes: a Manual of Basic Techniques, Pergamon Press, New York (1988); (3) Northern blot analysis for deteding expression of hdfA and/or hdfB mRNA in specific tissues and/or cells and 4) probes and primers that can be used as a diagnostic tool to analyse the presence of a nucleic acid hybridisable to the hdfA and/or hdfB probe in a given biological (e.g. tissue) sample.
  • tissue biological
  • Also encompassed by the invention is a method of obtaining a functional equivalent of an hdfA and/or hdfB gene or cDNA.
  • a method entails obtaining a labelled probe that includes an isolated nucleic acid which encodes all or a portion of the sequence according to SEQ ID NO: 2 or 5 or 19 or 22 or a variant thereof; screening a nucleic acid fragment library with the labelled probe under conditions that allow hybridisation of the probe to nucleic acid fragments in the library, thereby forming nucleic acid duplexes, and preparing a full-length gene sequence from the nucleic acid fragments in any labelled duplex to obtain a gene related to the hdfA and/or hdfB gene.
  • an hdfA and/or hdfB nucleic acid of the invention is at least 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more homologous to a nudeic acid sequence shown in SEQ ID NO: 1 , or 2, or 4 or 5 or 18, or 19, or 21 , or 22.
  • an hdfA and/or hdfB polypeptide of the invention is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more homologous to the amino acid sequence shown in SEQ ID NO: 3 or 6 or 20 or 23.
  • the invention relates to DNA sequences having SEQ ID NO: 1 , or 2, or 4, or 5, or 18, or 19, or 21, or 22 per se and to homologues thereof as defined above. DNA sequences related to these DNA sequences and obtained by degeneration of the genetic code are also part of the invention. DNA sequences related to DNA SEQ ID NO: 2, 5, 19, and 22 and obtained by hybridisation (see former paragraph) are also part of the invention. Isolated polypeptide encoded by these DNA sequences or homologues thereof as defined above are also part of the invention. Polypeptides hdfA and hdfB have a fundion involved in NHR. All these polypeptides can be used in the method of the invention to obtain filamentous fungi, which may have improved targeting efficiencies.
  • Genomic DNA oi Aspergillus niger strain CBS513.88 was sequenced and analyzed. Two genes with translated proteins annotated as homologues to KU70 and KU80, were identified and named hdfA and hdfB respedfvely. Sequences of the hdfA and MB loci, comprising the open reading frame (ORF) (with introns) and approximately 1000 bp 5' and 3' of the genes, are shown in sequence listings 1 and 4. Gene replacement vedors for hdfA and hdfB were designed according to known principles and constructed according to routine doning procedures (see figures 1 and 2).
  • these vedors comprise approximately 1000 bp flanking regions of the hdf ORFs for homologous recombination at the predestined genomic loci. In addition, they contain the A nidulans bi-directional amoS selection marker, in-between dired repeats.
  • the general design of these deletion vedors were previously described in EP635574B and WO 98/46772.
  • Example 2 Inactivation of the hdfA ⁇ ene in Asoe illus niger.
  • Linear DNA of deletion vedor pDEL-HDFA (figure 1) was isolated and used to transform Aspergillus niger CBS513.88 using method earlier described (Biotechnology of Filamentous fungi: Technology and Products. (1992) Reed Publishing (USA); Chapter 6: Transformation pages 113 to 156).
  • This linear DNA can integrate into the genome at the hdfA locus, thus substituting the hdfA gene by the amdS gene as depided in figure 3.
  • Transformants were seleded on acetamide media and colony purified according to standard procedures as described in EP635574B. Spores were plated on fluoro- acetamide media to select strains, which lost the amdS marker.
  • Example 3 Inactivation of the hdfB gene in Aspergillus niger.
  • Linear DNA of deletion vedor pDEL-HDFB (figure 2) was isolated and used to transform the Aspergillus niger strain CBS513.88. This linear DNA can integrate into the genome at the hdfB locus, thus substituting the hdfB gene for amdS (figure 4).
  • the same technique of gene replacement was used as the one described in example
  • Linear DNA of deletion vedor pDEL-HDFB (figure 2) was isolated and used to transform strain dHDFA. obtained in Example 2.
  • This linear DNA can integrate into the genome at the hdfB locus, thus substituting the hdfB gene for amdS (figure 4).
  • the technique of gene replacement used is the one described in example 2.Transformants were seleded on acetamide media and colony purified according to standard procedures. Spores were plated on fiuoro-acetamide media to select strains, which lost the amdS marker. Growing colonies were diagnosed by PCR for integration at the hdfB locus and candidate strains tested by Southern analyses for deletion of the hdfB gene.
  • hdfB gene Deletion of the hdfB gene was detectable by ⁇ 2,6 kb size redudion of DNA fragments covering the entire locus and hybridized to appropriate probes. Approximately 15 strains showed a removal of the genomic ⁇ cffB gene from a pool of approximately 380 initial transformants. Strain dHDFAB was seleded as a representative strain with both the hdfA and hdfB genes inadivated.
  • Example 5 Improved targeting for single homologous recombination events.
  • the second vedor contains the gene coding for phospholipase A1 (PLAI) from A. oryzae.
  • PLAI phospholipase A1
  • the gene encoding this enzyme has already been published (Watanabe I, et al, Biosd. Biotechnol. Biochem. (1999), Vol 63, numero 5, pages 820- 826).
  • This gene was cloned into pGBFINH using the same technique as described in WO 02/045524 for the cloning of the proline specific endoprotease gene in pGBFIN11- EPO.
  • Example 6 Improved targeting for double homologous recombination events at several different loci.
  • the targeting efficiency was further assessed by transformation of the dHDFA strain with deletion vectors designed for the inactivation of a number of amylase encoding genes from the genome. Gene-flanking regions were cloned essentially as described in Example 1, and the resulting vedors were linearised and used to transform protoplasts of CBS513.88 and the dHDFA strain.
  • the targeting frequency was assessed by PCR analyses and activity-based plate assays indicative of the inactivation of the corresponding genes. The latter was done by propagating transformants on PDA plates supplemented with 0.4% agar and subsequent staining with an iodine/potassium iodine solution (Lugol, Sigma L 6146). As can be seen in Table 1 below, the targeting frequency, as judged by PCR analyses and/or adivity-based plate assays indicative of the inactivation of the corresponding genes, was significantly improved over that observed with the CBS513.88 strain.
  • Example 7 The effect of size reduction of the homologous flanking regions of the amyBll gene on targeting frequencies.
  • Example 8 Phenotvpe analysis and production of polypeptide.
  • Solid media was the potato dextrose agar (PDA) medium (Difco, POTATO DEXTROSE
  • proline-pNA as a substrate.
  • 1U proline specific endoprotease is defined as the amount of enzyme which converts 1 micromol ZGIy(dne)-Pro(line)-pNA per min at pH 5 and at37°C.
  • PLA1 phospholipase PLA1 adivity from Aspergillus niger (PLA1) spedrophotometrically, an artificial substrate is used: 1,2-dithiodioctanoyl phophatidylcholine (diC8, substrate).
  • PLA1 hydrolyses the sulphide bond at the A1 position, dissociating thio-odano ⁇ c acid.
  • Thio-octano ⁇ c acid reads with 4,4 dithiopyridine (color reagent, 4-DTDP), forming 4-thiopyridone.
  • 4Thiopyridone is in tautomeric equilibrium with 4-mercaptopyridine, which absorbs radiation having a wavelength of 334 nm.
  • the extinction change at that wavelength is measured.
  • One unit is the amount of enzyme that liberates of 1 nmol thio-octano ⁇ c acid from 1,2- dithiodiodanoyl phosphatidylcholine per minute at 37°C and pH 4.0.
  • the substrate solution is prepared by dissolving 1 g diC8 crystals per 66 ml ethanol and add 264 ml acetate buffer.
  • the acetate buffer comprises 0.1 M Acetate buffer pH 3.85 containing 0.2% Triton-X100.
  • the colour reagent is a 11 mM 4,4-dithiodipyridine solution. It was prepared by weighting 5,0 mg 4,4-dithiodipyridine in a 2 ml eppendorf sample cup and dissolving in 1.00 ml ethanol. 1.00 ml of milli-Q water was added.
  • Example 9 Isolation of Penicillium mutants with improved efficiency for homologous recombination by mutagenesis To isolate mutants with an improved efficiency of gene targeting a combination of classical mutagenesis and molecular biology was applied. Penicillium chrysogenum (CBS 455.95) spores were obtained from colonies sporulating in YEPD (2% Yeast extrad from Difco, 1% pepton from Difco, 2% glucose).
  • CBS 455.95 Penicillium chrysogenum
  • YNB medium 0.67% w/v Yeast Nitrogen Base with amino acids (Difco), 2.0% w/v glucose
  • the mutagenesized populations were inoculated in YEPD medium. After germination the development of cells was followed using standard light microscopy. When the average hyphae of a culture was nicely developing, cells were harvested and incubated with lysing enzymes to obtain protoplasts. Protoplasts were transformed with two DNA fragments carrying expression cassettes of fundional seledion markers, ble and amdS.
  • the gene ble encodes a protein capable of conferring resistance to phleomycin (Kolar M, Punt PJ, van den Hondel CA, Schwab H.
  • chrysogenum are well known in the art and are described in many references, including Fi ⁇ kelstein and Ball (eds.), Biotechnology of filamentous fungi, technology and products, Butterworth- Heinemann (1992); Bennett and Lasure (eds.) More Gene Manipulations in fungi, Academic Press (1991); Turner, in: P ⁇ hler (ed), Biotechnology, second completely revised edition, VHC (1992).
  • the Ca-PEG mediated protoplast transformation is used as described in EP635574. To select targeted integration of these expression cassettes to specific loci in the Penicillium genome short homologous stretches of DNA were added via PCR on both sides of the DNA fragments.
  • the first type contains homologous stretches of DNA of 30 bp, the second of 50 bp and the third of 100bp. Selection was performed transforming mutants obtained from the nine sporulated batches with two DNA constructs pie and amdS) with 30, 50 or 100 bp homologous stredches defining 27 distind batches.
  • the ble gene was targeted to the niaD locus, thereby disrupting the nitrate reductase gene (Gouka RJ, van Hartingsveldt W, Bovenberg RA, van den Hondel CA, van Gorcom RF.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Mushroom Cultivation (AREA)

Abstract

The present invention relates to a method for increasing the efficiency of targeted integration of a polynucleotide to a pre-determined site into the genome of a filamentous fungal cell with a preference for NHR, wherein said polynucleotide has a region of homology with said pre-determined site, comprising steering an integration pathway towards HR. The present invention also relates to a mutant filamentous fungus originating from a parent cell, said mutant having an HR pathway with elevated efficiency and/or an NHR pathway with a lowered efficiency and/or a NHR/HR ratio with decreased efficiency as compared to said HR and/or NHR efficiency and/or NHR/HR ratio of said parent cell under the same conditions.

Description

Filamentous fungal mutants with improved homologous recombination efficiency Field of the invention
The invention relates to the field of molecular biology. It particularly relates to methods to improve the efficiency of directed integration of nucleic acids into the genome of a filamentous fungus and uses thereof. Background of the invention
Eukaryotic cells are preferred organisms for (recombinant) production of polypeptides and secondary metabolites. When constructing, for example, a protein production strain, the site of integration of the gene of interest coding for the protein to be produced is crucial for the regulation of transcription and/or expression of the integrated gene of interest. Since in most eukaryotic organisms integration of DNA into the genome occurs with high frequency at random, the construction of a protein production strain by recombinant DNA technology often leads to the unwanted random integration of the expression cassette comprising the gene encoding the protein to be produced. This uncontrolled "at random multiple integration" of an expression cassette is a potentially dangerous process, which can lead to unwanted modification of the genome of the host. It is therefore highly desirable to be able to construct a protein production strain by ensuring the correct targeting of the expression cassette with high efficiency. Furthermore, now that the sequence of complete genomes of an increasing amount of organisms is becoming available, this opens the opportunity to construct genorre spanning overexpression and deletion libraries. An important requirement for the efficient construction of such libraries is that the organism in question can be efficiently transformed and that the required homology needed to direct targeted integration of a nucleic acid into the genome is relatively short.
Eukaryotic cells have at least two separate pathways (one via homologous and one via non-homologous recombination) through which nucleic acids (in particular of course DNA) can be integrated into the host genome. The yeast Saccharomyces cerevisiae is an organism with a preference for homologous recombination (HR). The ratio of non- homologous to homologous recombination (NHR/HR) of this organism may vary from about 0.07 to 0.007.
WO 02/052026 discloses mutants of Saccharomyces cerevisiae having an improved targeting efficiency of DNA sequences into its genome. Such mutant strains are deficient in a gene involved in NHR (KU70).
Contrary to Saccharomyces cerevisiae, most higher eukaryotes such as filamentous fungal cells up to mammalian cell have a preference for NHR. Among filamentous fungi, the NHR/HR ratio is ranged between 1 and more than 100. In such organisms, targeted integration frequency is rather low. To improve this frequency, the length of homologous regions flanking a polynucleotide sequence to be integrated into the genome of such organisms has to be relatively long for example at least 2000bp for disrupting a single gene and at least 500bp for screening putative transformants. The necessity of such flanking regions represents a heavy burden when cloning the DNA construct comprising said polynucleotide and when transforming the organism with it. Moreover, neighbouring genes which lie within those flanking regions can easily be disturbed durhg the recombination processes following transformation, thereby causing unwanted and unexpected side-effects.
'-• Mammalian cells deficient in KU70 have already been isolated (Pierce et al, Genes and Development (2001), 15: 3237-3242). These mutants have a six-fold higher homology- directed repair frequency, but no increase in the efficiency of homologydirected targeted integration. This suggests that results obtained in organisms with a preference for HR (Saccharomyces cerevisiae) cannot be extrapolated to organisms with a preference for NHR.
Surprisingly, we found that steering the integration pathways of nucleic acids towards HR in filamentous fungi resulted in an improved efficiency for targeted integration of nucleic acids into the genome of filamentous fungi.
Brief description of the drawings Figure 1 depicts the replacement vector pDEL-HDFA used to inactive the hdfA gene in Aspergillus niger (A. nigeή. The replacement vector comprises theftα'/Α flanking regions, the amoS marker and E. coli DNA. The E. coli DNA was removed by digestion with restriction enzymes Ascl and Notl, prior to transformation of the A niger strains.
Figure 2 depicts the replacement vector pDEL-HDFB used to inactive the hdfB gene in A. niger. The replacement vector comprises fie hdfB flanking regions, the amdS marker and E. coli DNA. The E. coli DNA was removed by digestion with restriction enzymes Ascl and Notl, prior to transformation of the A. /./gerstrains .
Figure 3 depicts the strategy used to delete the hdfA gene of A. riger. The DNA construct used comprises the a cfS selection marker flanked by homologous regions (5' and 3') of the hdfA gene (1). This construct integrates through double homologous recombination (X) at the genomic hdfA locus (2) and replaces the genomic hdfA gene copy (3). Subsequentiy, recombination over the direct repeats (J) removes the amdS marker, resulting in precise excision of hehdfA gene (4).
Figure 4 depicts the strategy used to delete the hdfB gene of A. niger. The DNA construct comprises the amdS selection marker flanked by homologous regions (5' and 3') of the hdfB gene (1). T is construct integrates through double homologous recombination (X) at the genomic ΛdfB locus (2) and replaces the genomic hdfB gene copy (3). Subsequently, recombination over the direct repeats J) removes the amdS marker, resulting in precise excision of the/7c//B gene (4).
Figure 5 depicts the schematic strategy used to integrate a DNA construct into the genome of A niger through single homologous recombination. The expression vector comprises the selectable amdS marker and a gene of interest flanked by homologous regions of the glaA locus (3' glaA and 3" glaA respectively) to direct integration at the genomic glaA locus.
Description of the invention All patents and publications, including all sequences and methods disclosed within such patents and publications, referred to herein are expressly incorporated by reference. These patents and publications include: EP 357 127 B, EP 635 574 B, WO 97/06261, WO 98/46772. Method for increasing the efficiency of targeted integration of a polynucleotide into the genome of a filamentous fungal cell
The present invention provides a method for increasing the efficiency of targeted integration of a polynucleotide to a pre-determined site into the genome of a filamentous fungal cell, with a preference for NHR, wherein said polynucleotide has a region of homology with said pre-determined site comprising steering an integration pathway towards HR. The present invention arrives at such steering either by elevating the efficiency of the HR pathway, and/or by lowering (meaning reducing) the efficiency of the NHR pathway and/or by decreasing the NHR HR ratio.
In the context of the invention, the HR pathway is defined as all genes and elements being involved in the control of the targeted integration of polynucleotides into the genome of a host, said polynucleotides having a certain homology with a certain predetermined site of the genome of a host wherein the integration is targeted The NHR pathway is defined as all genes and elements being involved in the control of the integration of polynucleotides into the genome of a host, irrespective of the degree of homology of the said polynucleotides with the genome sequence of the host.
According to a preferred embodiment, the steering comprises providing a mutant of a parent filamentous fUngal cell, wherein the NHR/HR ratio is decreased in the mutant of at least 5% as compared to said ratio in said parent organism as measured by the following assay. More preferably, the NHR/HR ratio is decreased in the mutant of at least
10%, even more preferably at least 50% and most preferably at least 100% as compared to said ratio in said parent organism. According to another preferred embodiment, tie filamentous fungal cell of the invention has a ratio NHR/HR, which is at least 200, at least 50, at least 10 as measured by the following assay. Preferably the ratio of the filamentous fungal cell is at least 1, more preferably at least 0.5, even more preferably at least 0.1, even more preferably at least
0.05, even more preferably at least 0.01 even more preferably at least 0.005 even more preferably at least 0.001 even more preferably at least 0.0005 even more preferably at least O.0001 and most preferably at least 0.00001.
According to a more preferred embodiment, the filamentous fungal cell of the invention has a ratio NHR/HR, which is less than 200, even more preferably less than 50, less than "10 as measured by the following assay. Even more preferably the ratio of the filamentous fungal cell is less than 1, even more preferably less than 0.5, even more preferably less than 0.1 , even more preferably less than 0.05, even more preferably less than O.O 1 even more preferably less than 0.005 even more preferably less than 0.001 even more preferably less than 0.0005 even more preferably less than 0.0001 and most preferably less than 0.00001.
The ratio of NHR HR is preferably measured by the assay as described in WO 02/052026 (table 2, p23). According to a preferred embodiment, the parent organism is one of the filamentous fungus cells as defined under the section host cell. According to another preferred embodiment, the filamentous fungus cell of the invention originates from a species as defined under the section host cell.
Alternatively and according to a less preferred embodiment, the NHR/HR ratio in a filamentous fungus is monitored using techniques known to the skilled person such as transcriptional profiling and/or northern blotting and/or western blotting of at least one of the following components involved in such pathways: KU70, KU80, MRE11, RAD50, RAD51, RAD52, XRS2, SIR4, LIG4.
In the context of this invention, "a region of homology" means "at least one" region of homology. A pre-determined site is herein defined as a site within the genetic material contained by a host cell to which a polynucleotide with homology to this same site is integrated with a method according to the invention.
In a preferred embodiment, the invention provides a method for increasing the efficiency of targeted integration of a polynucleotide to a pre-determined site into the genome of a filamentous fungal cell with a preference for NHR, wherein said polynucleotide has a region of homology with said predetermined site comprising steering an integration pathway towards HR by providing a filamentous fungus, wherein the efficiency of the NHR pathway has been lowered and/or the NHR/HR ratio has been decreased compared to the efficiency of the NHR pathway and/or the NHR/HR ralo of the filamentous fungus it originates from under the same conditions. According to a preferred embodiment, the parent organism is one of the filamentous fungus as defined under the section host cell. The efficiency of the NHR pathway is preferably measured in the assay as described in WO02/052026 (table 2, p23).
Alternatively and according to a less preferred embodiment, the efficiency of the NHR pathway in a filamentous fungus is monitored using techniques known to the skilled person such as transcriptional profiling and/or northern blotting and/or western blotting of components involved in such pathway. More preferably, the expression level of at least one of the following components is monitored: KU70, KU80, MRE11, RAD50, RAD51, RAD52, XRS2, SIR4, LIG54. Even more preferably, the expression level of homologous components of the KU complex is monitored. Most preferably, the expression level of homologous KU70 and/or KU80 is monitored.
A lowered NHR efficiency means at least lower than in the parenta cell the obtained cell originates from. Preferably, lowered means twice lower, more preferably ten times lower, even more preferably 10O times lower, most preferably more than 1000 times lower and even most preferably not detectable using northern or western blotting, array techniques or a phenotypic screen.
A typical phenotypic screen that could be used comprises the following steps: transforming the putative NHR mutants with an expression cassette comprising a selection marker gene flanked by homologous sequences of a predetermined genomic site. The selection marker gene used in this phenotypic screen can be selected from a number of marker genes that are useful for transformation of filamentous fungi. By way of example these markers include but are not limited to dominant and bi-directional selection marker gene such as an acetamidase IpmdS ) gene (EP 635 574 B or WO 97/06261), auxotrophic marker genes such as argB, trpC or pyrG and antibiotic resistance genes providing resistance against e.g. phleomyα'n (the product encoded by the ble gene confers resistence to phleomycine), hygromycin B or G418. A preferred selection marker gene is the ble gene encoding a protein conferring resistence to phleomycin. The putative NHR mutants already contain at this piedetermined genomic site a birectional selection marker gene such as an amdS gene, nitrate reductase gene (niaD), sulphate permease (Sut B) gene or PyrG gene. The niaD gene has already been described elsewhere (Gouka RJ, van Hartingsveldt W, Bovenberg RA, van den Hondel CA, van Gorcom RF. Cloning of the nitrate-nitrite reductase gene cluster of Penicillium chrysogenum and use of the niaD gene as a homologous selection marker. J Biotechnol. 1991 Sep;20(2): 189-99). The niaD gene enables direct selection of transformants on plates containing chlorate, as cells become resistant to chlorate. The sutB gene has already been described elsewhere (van de Kamp M, Pizzinini E, Vos A, van der Lende TR, Schuurs TA, Newbert RW, Turner G, Konings WN, Driessen AJ. Sulfate transport in Penicillium chrysogenum: cloning and characterization of the sutA and sutB genes. J. Bacteriol. 1999 Dec;181(23):722S-34), A preferred selection marker gene is the A.nidulans amdS coding sequence fused to the A.nidulans gpdA promoter (EP635 574 B). AmdS genes from other filamentous fungi may also be used (WO 97/06261). In the preferred form of the phenotypic screen, the amdS gene is present at the predetermined genomic site and the ble gene is used as the gene to be targeted to the predetermined site. In non-HR-improved mutants the όfe-cassette will integrate randomly in the genome, enabling many transformants to grow on a double selective medium with both acetamide and phleomycin; and relatively few transformants to grow on fluoracetamide- phleomycin plates. In mutants with improved HR there will be a limited number of transformants on the acetamide— phleomcycin double selective plates as the amdS- cassette is efficiently exchanged with the We-cassette. In this case more mutants will appear on fluoracetamide-phleomycin double selective plates.
According to another preferred embodiment, the filamentous fungus having a lowered NHR efficiency and/or a decreased NHR/HR ratio is a filamentous fungus wherein a component involved in NHR has been inhibited. In this context, "a" means "at least one": at least one component involved in NHR has been inhibited in a given filamentous fungus. Inhibition can be achiev&d by down regulating the expression level of a gene involved in NHR or inactivating a gene encoding a component involved in NHR and/or by down regulating the expression level of a component involved in NHR, and/or (temporarily) decreasing the (protein) activity of a component involved in NHR and a combination of these possibilities.
Preferably, the filamentous fungus obtained has the expression of a gene involved in NHR down regulated by comparison to the expression of said gene in the parent filamentous fungal cell it originates from under the same conditions. According to a preferred embodiment, tie parent filamentous fungus is one of the filamentous fungus as defined under the section host cell.
The expression level of a gene, or a DNA sequence is down regulated when the expression level of this specific gene or DNA sequence in the obtained filamentous fungus is lower than the expression level of the same gene or DNA sequence in the parental filamentous fungus it originates from, preferably three times lower, more preferably four times lower, most preferably more than four times lower and even most preferably not detectable using northern, or western blotting or 'omics' techniques like transcriptomics and proteomics.
The down and/or up regulation of the expression level of a DNA sequence can be monitored by quantifying the amount of corresponding mRNA present in a cell by northern blotting (in Molecular Cloning: A Laboratory Manual, Sambrook et al., New York: Cold Spring Harbour Press, 1989) for example and/or by quantifying the amount of corresponding protein present in a cell by western blotting for example. The difference in mRNA amount may also be quantified by DNA array analysis (Eisen, M.B. and Brown, P.O. DNA arrays for analysis of gene expression. Methods Enzymol. 1999:303:179- 205).
The down regulation of the expression level of at least one gene or DNA sequence may be obtained by genetic manipulation by one of the following techniques or by a combination thereof: a. using recombinant genetic manipulation techniques, b. submitting the filamentous fungus to mutagenesis. Alternatively or in combination with above-mentioned techniques and according to another preferred embodiment, the down regulation of the expression level of at least one gene or DNA sequence may be obtained by submitting the filamentous fungus to a inhibiting compound/composition. The filamentous fungus obtained may be subsequently selected by monitoring the expression level of said gene or DNA sequence. Optionally, the filamentous fungus is subsequently selected by measuring its efficiency of the NHR and/or of the HR pathways and/or its NHR/HR ratio. In the context of the invention, the efficiency of the HR pathway of a filamentous fungus may be measured by the efficiency of the targeted integration of a given poynucleotide sequence into a predetermined site in the genome of the filamentous fungus using given homology region(s). In the context of the invention, the efficiency of the NHR pathway of a filamentous fungus may be measured by the efficiency of the non targeted integration of a given polynucleotide sequence in the genome of the filamentous fungus irrespective of any homology region(s). More preferably, the down regulation of the expression of st least one DNA sequence is made with recombinant genetic manipulation techniques such as defined in step a. to obtain a recombinant filamentous fungus. Most preferably step a. comprises deleting the DNA sequence, even most preferably the deleted DNA sesquence is replaced by a non- functional variant thereof, and even most preferably the deletion and replacement are made by gene replacement preferably as described in EP 357127 B. In cases of deletion or replacement of at least one DMA sequence of the chosen filamentous fungus, an appropriate DNA sequence has to be introduced at the target locus. The target locus is in this case the DNA sequence involved in NHR pathway to be deleted or replaced. The appropriate DNA sequence is preferably present on a cloning vector. Suitable cloning vector are the ones that are able to integrate at the predetermined target locus in the chromosomes of the filamentous fungal host cell used. Preferred integrative cloning vector comprises a DNA fragment, which is homologous to the DNA sequence to be deleted or replaced for targetjngi the integration of the cloning vector to this pre-determined locus. In order to promote targeted integration, the cloning vector is preferably linearized prior to transformation of the host cell. Preferably, linearization is performed such that at least one but preferably either end of the cloning vector is flanked by sequences homologous to the DNA sequence to be deleted or replaced. The length of the homologous sequences flanking the DMA sequence to be deleted or replaced is preferably less than 2 kb, even prefenafeιlγ_ less than 1 kb, even more preferably less than O.δkb, even more preferably Jess than 0.2kb, even more preferably less than 0.1 kb, even more preferably less than 50bp and most preferably less than 30bp. The selection marker gene in the cloning vector can be selected from a number of marker genes that are useful for transformation of filamentous fungi. By way of example these markers include but are not limited to dominant and bi-directional selection marker gene such as an acetamidase (amdS) gene (EP 635 574 B or WO 97/06261), auxotrophic marker genes such as argB, trpC, or pyrG and antibiotic resistance genes providing resistance against e.g. phleomycin, hygromycin B or G418. A preferred selection marker gene is the A.nidulans amdS coding sequence fused to the A.nidulans gpdA promoter (EP635 574 B). AmdS genes from other filamentous fungus may also be used (WO 97/06261). The amdS selection marker gene has the advantage it can be used several times in the same strain to replace and/or delete distinct DNA sequences. By means of counterselection on fluoracetamide media as described in EP 635 574 B, the resulting strain is marker free and can be used for further gene modifications. A preferred strategy for down regulating the expression of a given DNA sequence comprises the deletion of the wild type DNA sequence and/or replacement by a modified DNA sequence, whose expression product is not functional. The deletion and the replacement are preferably performed by the gene replacement technique described in EP 0 357 127 BLThe specific deletion of a gene is preferably performed using the amdS gene as selection marker gene as described in EP 635574 B.
Alternatively or in combination with other mentioned techniques, a tectinique based on in vivo recombination of cosmids in E. coli can be used, as described in: A rapid method for efficient gene replacement in the filamentous fungus AspergillLrs nidulans (2000) Chaveroche, MK., Ghico, J-M. and d'Enfert C; Nucleic adds Research, vol 28, no 22. This technique is applicable to other filamentous fungi like for example A niger.
Down regulating the expression of a DNA sequence may also be achieved by using anti sense nucleic acids, or by UV or chemical mutagenesis (Mattern, I.E., van Noort J.M., van den Berg, P., Archer, D. B., Roberts, LN. and van den Hondel, C A., Isolation and characterization of mutants of Aspergillus niger deficient in extracellular proteases. Mol Gen Genet. 1992 Aug;234(2):332-6.).
Preferably, the deficiency brought in the NHR pathway is an inducible one. This can be reached by replacing the endogenous regulatory egions of the gene encoding the component involved in NHR by new regulatory regions, preferably by using a repressible or regulatable promoter, more preferably by using a promoter that can be switch on/off: by glucose repression, or ammonia repression, or pH repression. Examples of glucose- repressed promoters are the Penicillium chrysogenum pcbAB promoter (Martin JF, Casqueiro J, Kosalkova K, Marcos AT, Gutierrez S. Penicillin and cephalosporin biosynthesis: mechanism of carbon catabolite regulation of penicillin production. Antonie Van Leeuwenhoek. 1999 Jan-Feb;75(1-2):21-31. Review.) or the Aspergillus niger glucoamylase promoter. Examples of on/off switchable promoters are described in the following publications:
- An activator/repressor dual system allows tight tetracycline-regulated gene expression in budding yeast: Belli et al, (1998) Nucl. Acid Research, vol 26, n.4:942-947, - A light-switchable gene promoter system: Shimizu-Sato_et al, (2002) Nat. Biotech. Vol 20, no 10:1041-1044.
According to a preferred embodiment, the filamentous fungus is deficient in at least one of its endogenous genes, which are homologous with the following yeast genes involved in the NHR pathway KU70, KU80, RAD50, MRE11, XRS2 and SIR4 (van den Bosch ot al (2002): DNA double-strand break repair by homologous recombination. Biol. Chern. Vol.383:873-892 and Allen et al, (2003): Interactive competition between homologous recombination and non-homologous end joining. Mol. Cancer Res., vol 1:913-920). All kinds of mutants having at least one component involved in NHR, which is no longer capable or at least significantly less capable to perform its function in the process of NHR, are mutants contemplated by the present invention. Preferably, the component involved in NHR has been hhibited so that the efficiency of the NHR pathway in trie obtained mutant is less than 90% of the activity in the parent cell it originates from under the same conditions as measured in the assay defined earlier, even preferably less than 85%, more preferably less than 80%, even more preferably less than 70%, most preferably less than 50%.
According to a preferred embodiment, the parent filamentous fungus is one of filamentous fungus as defined under the section host cell.
Preferably, the filamentous fungus cell is deficient in at least one of the following genes z
- hdfA as identified in SEQ ID NO: 2 or 19 or homologues thereof, or
- hdfB as identified in SEQ ID NO: 5 or 22 or homologues thereof, or or both.
According to another preferred embodiment, the filamentous fungus has the amount of at least one of the proteins encoded by these genesήdf.4 and hdfB that is decreased upon induction.
According to another preferred embodiment, the down regulation of the expression level of at least one gene or DNA sequence may be obtained by genetic modification by submitting the filamentous fungus to mutagenesis. Filamentous fungal cells may be subjected to random mutagenesis and subsequently to a selection assay to isolate trie mutants with improved HR from the whole diverse population of mutants. According to a preferred embodiment of the present invention, one of the filamentous fungal cell defined under the sedion host cell is used as starting strain to perform the mutagenesis.
For example, the starting strain is subjected to UV irradiation so that the survival percentage is ranged between 0.001% and 60%. Preferably, the survival percentage is ranged between 0.01% and 50%. It is well known to the skilled person that conidiospores is the preferred material to mutagenize filamentous fungi by physical or chemical means. Mutants may however also be obtained from mycelium cells. Also, other mutagenic treatments than UV can be applied as chemical agents (e.g. NTG). The seledion method described herein may be applied to select mutants obtained from either conidiospores or mycelium cells.
Preferably the mutagenesis is applied to conidiospores. UV irradiation is preferably applied for different times such as 7.5, 15 and 30 minutes to obtain mild, medium and strong mutation rate levels in the cells. The mutated samples may either be directly re- sporulated or incubated for an extended recovery period in a rich medium such as YNF3 or YEPD (see definition in example. 9) before sporulation was induced (for example as described in example 9).
The sporulated batches may be then tested for their efficiency in gene targeting. This could be tested by the following method. Protoplasts may be transformed with at least one, preferably two or more DNA fragments carrying expression cassettes rf functional selection markers. The selection marker genes in the expression cassettes can bo seleded from a number of marker genes that are useful for transformation of filamentou s fungi. By way of example these markers indude but are not limited to dominant and bi - directional selection marker gene such as an acetamidase (amdS) gene (EP 635574 F3 or WO 97/06261), auxofrophic marker genes such as argB, trpC, or pyrG and antibiotic resistance genes providing resistance against e.g. phleomycin, hygromycin Bor G41S-- Preferably the seledion markers used are the ble and amdS genes. The amdS cassette used is the A.nidulans coding sequence fused to the A.nidulans gpdA promoter (EP635 574 B). amdS genes from other filamentous fungus may also be used (WO 97/06261)-. The gene bb encodes a protein capable of conferring resistance to phleomycin. The gene amdS encodes a protein enabling cells to grow on acetamide as the sole nitrogen source (as described in EP635 574B). Techniques applied for the transfer of DNA to protoplasts of filamentous fungi are well known in the art and are described in many references, including Finkelstein and Ball (eds.), Biotechnology of filamentous fungi , technology and products, Butterworth-Heinemann (1992); Bennett and Lasure (eds.) More Gene Manipulations in fungi, Academic Press (1991); Turner, in: Pϋhler (ed), Biotechnology, second completely revised edition, VHC (1992). The Ca-PEG mediated protoplast transformation is used as described in EP635574B. To seled targeted integration of these two expression cassettes to two distinct spedfic loci in the filamentous fungi genome short homologous stretches of DNA may be added for example via PCR on both sides of the DNA fragments. Several types of construct could be made to improve the chances to seled a mutant having an improved targeting efficiency: the homologous stretches of DNA could typically vary from 30bp to 1000bp, preferably 30bp to 700bp, more preferably 30bp to 500bp, even more preferably 30bp to 300bp, more preferably preferably 30bp to 200bp, even more preferably 30bp to 100 bp and most preferably 30bp. In theory all loci in the filamentous fungi genome could be chosen for targeting integration of the expression cassettes. Preferably, the locus wherein targeting will take place is such that when the wild type gene present at this locus has been replaced by the gene comprised in the expression cassette, the obtained mutant will display a change detedable by a given assay. Preferably the locus is the niaD locus, thereby disrupting the nitrate reductase gene (Gouka RJ, van Hartingsveldt W, Bovenberg RA, van den Hondel CA, van Gorcom RF. Cloning of the nitrate-nitrite reductase gene duster of Penicillium chrysogenum and use of the niaD gene as a homologous selection marker. J Biotechnol. 1991 Sep;20(2): 189-99), enabling direct selection of transformants on plates containing chlorate, as cells become resistant to chlorate. Another preferred locus is the sutB locus, thereby disrupting the sulphate permease gene (van de Kamp M, Pizzinhi E, Vos A, van der Lende TR, Schuurs TA, Newbert RW, Turner G, Konings WN, Driessen AJ. Sulfate transport in Penicillium chrysogenum: cloning and charaderization of the sutA and sutB genes. J. Bacteriol. 1999 Dec;181(23):7228-34), enabling dired selecfon of transformants on plates containing selenate. Mutants with both selection markers present and having the two alterations resulting from the inadivation of the genes present at the integration lod are strains with improved targeted integration.
According to another preferred embodiment, the mutant filamentous fungus having a lowered efficiency in the NHR pathway, or a decreased NHR/HR ratio and/or an elevated efficiency of the HR pathway is obtained by decreasing, more preferably partially or most preferably completely inhibiting a component involved in NHR. Partial or complete inhibition of a component involved in NHR can be obtained by different methods, for example by an antibody directed against such a component or a chemical inhibitor or a protein inhibitor or a physical inhibitor (Tour O. et al, (2003) Nat. Biotech: Genetically targeted chromophore-assisted light inactivation. Vol.21. no. 12:1505-1508) or peptide inhibitor or an anti-sense molecule or RNAi molecule (R.S. Kamath_et al, (2003) Nature: Systematic functional analysis of the Caenorhabditis elegans genome using RNAi.vol. 421, 231-237). Irrespective of the kind of (partial or more preferably complete) inhibition it is important that a component involved in NHR is no longer capable or at least significantly less capable to perform its function in the process of NHR as defined above.
Components involved in NHR comprise filamentous fungal homologues of yeast KU70, RAD50, MREII, XRS2, LIG4, SIR4, KU80, LIFL or NEIL or associating component.. Because the nomenclature of genes differs between organisms a functional equivalent or a functional and/or a functional fragment thereof, all defined herein as being capable of performing (in fundion, not in amount) at least one function of the yeast genes KU70, RAD50, MREII, XRS2, LIG4, SIR4, KU80, LIFL or NEIL are also induded in the present invention. By transiently (partially or more preferably completely) inhibiting a component involved in NHR a nudeic acid is integrated at any desired position without permanently modifying a component involved in NHR and preventing unwanted side effects caused by the permanent presence of such a modified component involved in NHR. In addition of the above-mentioned techniques or as an alternative, it is also possible to obtain a lowered NHR efficiency by inhibiting the adivity of proteins, which are involved in NHR or to re-localize the NHR involved proteins by means of altemative signal sequences (Ramon de Lucas, J., Martinez O, Perez P., Isabel Lopez, M., Valenciano, S. and Laborda, F. The Aspergillus nidulans carnitine carrier encoded by the acuH gene is exclusively located in the mitochondria. FEMS Microbiol Lett. 2001 Jul 24;201(2):193-8.) or retention signals (Derkx, P. M. andMadrid, S. M. The foldase CYPB is a component of the secretory pathway of Aspergillus niger and contains the endoplasmic reticulum retention signal HEEL. Mol. Genet. Genomics.2001 Dec;266(4):537-45.).
Alternatively or in combination with above-mentioned techniques, inhibition of protein activity can also be obtained by UV or chemical mutagenesis (Mattern, I.E., van Noort J.M., van den Berg, P., Archer, D. B., Roberts, l.N. and van den Hondel, C. A., Isolation and characterization of mutants of Aspergillus niger deficient in extracellular proteases. Md Gen Genet. 1992 Aug;234(2):332-6.) cr by the use of inhibitors like the proteasomal inhibitor of Affinity (clasto-ladacystin-β-lactone, Affinity Research Products Ltd., CW8405-Z02185.).
According to another preferred embodiment, the steering towards HR comprises adding an excess of small double stranded polynucleotides able to bind and thereby limit the expression of NHR components, next to the polynudeotide to be integrated (Agrawal N. et al,: RNA interference: biology, mechanism and applications. Microbiol. Mol. Biol. Rev., vol. 67, no. 4:657-685).
In a preferred embodiment the invention provides a method for increasing the efficiency of targeted integration of a polynudeotide to a pre-determined site, whereby said polynucleotide has homology at or around the said pre-determined site, in a filamentous fungus with a preference for NHR comprising steering an integration pathway towards HR by providing a filamentous fungal cell, wherein the effidency of the HR pathway has been elevated compared to the one of the parent filamentous fungus it originates from under the same conditions. The efficiency of the HR pathway is preferably assayed by the same assay as the one used for determining the NHR HR ratio. According to a preferred embodiment the parent organism is one of the filamentous fungi as defined in the section host cell.
Elevated means at least higher than in the parental cell the obtained cell originates from. Preferably, elevated means twice higher, more preferably three times higher, even more preferably four times higher, most preferably more than four times higher using northern, or western blotting or array technique or a phenotypic screen.
According to another preferred embodiment, the filamentous fungus has the expression level of at least one gene involved in HR, which has been up regulated by comparison to the expression level of the same gene in the filamentous fungal cell it originates from. This can be achieved by increasing the expression level of a gene encoding a component involved in HR and/or by increasing the expression level of a component involved in HR and/or by (temporarily) increasing the activity of the component involved in HR. Preferably, the filamentous fungus obtained has the expression of a gene involved in HR, which has been up regulated by comparison to the expression of said gene in the filamentous fungal cell it originates from.
The expression level of a DNA sequence is up regulated when the expression level of this specific DNA sequence in the obtained filamentous fUngus is higher than the expression level of the same DNA sequence in the parental filamentous fungus it originates from , preferably three times higher, more preferably four times higher, most preferably more than four times higher using northern, or western blotting or array technique. According to a preferred embodiment, the parent organism is one of the filamentous fungi as defined in the section host cell.
The up regulation of the expression level of at least one DNA sequence may be obtained by genetic manipulation by one of the following techniques or by a combination thereof: c. using recombinant genetic manipulation techniques, d. submitting the filamentous fUngus to mutagenesis,
Alternatively or in combination with above-mentioned techniques and according to another preferred embodiment, the up regulation of the expression level of at least one gene or DNA sequence may be obtained by submitting the filamentous fungus to an activating compound/composition.
The filamentous fungus may be subsequently selected by monitoring the expression level of said DNA sequence and optionally the efficiency of the HR pathway of the filamentous fungus. The HR efficiency of a filamentous fungus may be measured by the effidency of the targeted integration of a given polynucleotide sequence into a pre- determined site in the genome of the filamentous fungus using given homology region(s).
Preferably, the up regulation of the expression of at least one DNA sequence is made with recombinant genetic manipulation techniques such as defined in step a. to obtain a recombinant filamentous fungus. Preferably step a. comprises transforming the filamentous fungus with a DNA construd comprising the DNA sequence, preferably said DNA sequence being operationally linked to a promoter of a highly expressed gene. The chosen promoter may be stronger than the endogenous promoter of the DNA sequence to be over expressed. The promoter for expression of the DNA sequence is preferably derived from a highly expressed fungal gene.
A number of preferred highly expressed fungal genes are given by way of example: the amylase, glucoamylase, alcohol dehydrogenase, xylanase, glyceraldehyde-phosphate dehydrogenase or cellobiohydrolase genes from Aspergilli or Trichoderma Most preferred highly expressed genes for these purposes are an Aspergillus niger glucoamylase gene, an Aspergillus oryzae TAKA-amylase gene, an Aspergillus nidulans gpdA gene or a Trichoderma reesei cellobiohydrolase gene. A glucoamylase promoter is the most preferred promoter to be used. These highly expressed genes are suitable both as target loci for integration of cloning vedors and as source of highly expressed fungal genes.
According to another preferred embodiment, step a. comprises increasing the copy number of the DNA sequence into the filamentous fungal cell, preferably by integrating into its genome copies of the DNA sequence, more preferably by targeting the integration of the DNA sequence at a highly expressed locus, preferably at a glucoamylase locus.
The up regulation of the expression of the DNA sequence may be reached by increasing the copy number of the DNA sequence by introducing at least one copy of the DNA sequence into the filamentous fungus or by changing for a stronger promoter or changing for a gene encoding a protein with better kinetics and/or lifetime. The DNA sequence may be present on a plasmid or integrated into the genome. The skilled person can choose amongst two alternative possibilities: - over express at least one endogenous DNA sequence of the filamentous fungus being involved in the HR pathway. In this case, the filamentous fungus comprises several copies of its endogenous DNA sequence. over express at least one heterologous DNA involved in HR. In this case, the filamentous fungus would have its endogenous DNA sequence involved in HR and, in addition at least one copy of a heterologous DNA sequence involved in HR.This heterologous DNA sequence is an homologue of its corresponding endogenous DNA sequence.
The filamentous fungus can be transformed with one or more copy of the DNA sequence (derived from inter alia Tilbum et al, 1983, Gene, 26:205-221). The DNA sequence can be either stably integrated into the genome of the filamentous fungus or introduced into the cell as part of a DNA molecule capable of autonomous replication The DNA sequence is preferably present on a doning vedor. Any cloning vector capable of transforming a filamentous fungal host cell is suitable for use in the present invention. Cloning vectors for use in the invention thus comprise integrative cloning vectors, which integrate at random or at a predetermined target locus in the chromosomes of the filamentous fungal host cell, as well as autonomously maintained doning vectors such as vectors comprising the AMA1-sequence In a preferred embodiment of the invention, the integrative doning vector comprises a DNA fragment, which is homologous to a DNA sequence in a predetermined target locus in the genome of the filamentous fungal host cell for targeting the integration of the cloning vector to this predetermined locus. In order to promote targeted integration, the cloning vector is preferably linearized prior to transformation of the host cell. Linearization is preferably performed such that at least one but preferably either end of the doning vector is flanked by sequences homologous to the target locus. The length of the homologous sequences flanking the target locus is preferably at least 30bp, preferably at least 50 bp, preferably at least 0.1kb, even preferably at least 0.2kb, more preferably at least 0.5 kb, even more preferably at least 1 kb, most preferably at least 2 kb.
Preferably, the DNA sequence in the doning vector, which is homologous to the target locus is derived from a highly expressed locus meaning that it is derived from a gene, which is capable of high expression level in the filamentous fungal host cell. A gene capable of high expression level, i.e. a highly expressed gene, is herein defined as a gene whose mRNA can make up at least 0.5% (w/w) of the total cellular mRNA, e.g. under induced conditions, or alternatively, a gene whose gene product can make up at least 1% (w/w) of the total cellular protein, or, in case of a secreted gene product, can be secreted to a level of at least 0.1 g/l (as described in EP 357 127 B1). To increase even more the number of copies of the DNA sequence to be over expressed the technique of gene conversion as described in W098/46772 may be used. The skilled person will appreciate the possibility that the homologous DNA sequence for targeting and the promoter sequence can coincide in one DNA fragment. The list of highly expressed genes given above is also suited as target locus.
An example of an autonomously maintained cloning vector is a cloning vedor comprising the AMA1 -sequence. AMA1 is a 6.0-kb genomic DNA fragment isolated from Aspergillus nidulans, which is capable of Autonomous Maintenance in Aspergillus (see e.g. Aleksenko and Clutterbuck (1997), Fungal Genet. Biol.21: 373-397). According to another preferred embodiment of the method of the invention, step a. comprises transforming the filamentous fungus with a DNA construct comprising a selection marker gene. The selection marker gene in the cloning vector can be selected from a number of marker genes that are useful for transformation of filamentous fungi. By way of example these markers include but are not limited to dominant and bi- diredional seledion marker genes such as an amdS gene (EP 635574, WO 97/06261), auxotrophic marker genes such as argB, trpC, or pyrG and antibiotic resistance genes providing resistance against e.g. phleomycin, hygromycin B or G418.The use of a dominant and bi-directional selection marker gene is preferred. Preferably an amdS gene is preferred, more preferably an amdS gene from Aspergillus nidulans or Aspergillus niger. A most preferred selection marker gene is VheA.nidulans amdS coding sequence fused to the A.nidulans gpdA promoter (see EP635574). AmdS genes from other filamentous fungus may also be used (WO 97/06261). The amdS seledion marker gene has the advantage it can be used several times in the same strain to introduce, over express and/or delete distinct DNA sequences. By means of counterseledion on fluoracetamide media as described in EP 635574, the resulting strain is marker free and can be used for further gene modifications. Alternatively or in addition with above-mentioned techniques, up regulation of the expression of a DNA sequence can be reached using UV or chemical mutagenesis (Mattern, I.E., van Noort J.M., van den Berg, P., Archer, D. B., Roberts, LN. and van den Hondel, C. A., Isolation and characterization of mutants of Aspergillus niger deficient in extracellular proteases. Mol Gen Genet 1992 Aug;234(2):332-6.).
In addition and/or in combination with up regulation of expression of DNA sequences involved in HR, it is also possible to obtain an increased HR effidency by increasing the activity of proteins involved in HR by UV or chemical mutagenesis (Mattern, I.E., van Noort J.M., van den Berg, P., Archer, D. B., Roberts, LN. and van den Hondel, C. A., Isolation and characterization of mutants of Aspergillus niger deficient in extracellular proteases. Mol Gen Genet 1992 Aug;234(2):332-6.) .
The skilled person would understand that to achieve the up regulation of the expression of a DNA sequence, one may use each of the described technique either separately or in combination. The skilled person would also understand that to obtain a filamentous fungus with an increased HR/NHR ratio, and/or with a lowered NHR dficiency and/or an elevated HR efficiency, one may use at least one of each technique described for respectively down and up regulating the expression of a given gene in a filamentous fungus. Preferably, all the techniques performed on the filamentous fungus to obtain a recombinant filamentous fungus having both a lowered NHR efficiency and an elevated HR efficiency have been performed using a dominant and bi-directional selection marker, preferably an amdS gene more preferably an amdS gene from Aspergillus nidulans or Aspergillus niger. The obtained filamentous fungus may be subsequently selected by monitoring the expression level of said DNA sequence as described before by using for example northern and/or western blotting and/or array and/or phenotype screening. Optionally, the efficiency of the NHR and/or HR pathways of the cell is monitored. The efficiency of these pathways of a filamentous fungus may be monitored as defined earlier on.
Preferably, the modification brought in the HR pathway is an indudble one. This can be reached by replacing the endogenous regulatory regions of the gene encoding the component involved in HR by indudble regulatory regions, preferably by using an indudble promoter. Examples of indudble promoters are the glucoamylase promoter of Aspergillus niger, the TAKA amylase promoter of Aspergillus oryzae, the paf promoter (Marx,F., Haas.H., Reindl.M., Stoffier.G., Lottspeich.F. and Redl.B. Cloning, structural organization and regulation of expression of the Penicillium chrysogenum paf gene encoding an abundantly secreted protein with antifungal activity Gene 167 (1-2), 167- 171 (1995) or the pcbC promoter of Penicillium chrysogenum (Martin JF, Casqueiro J, Kosalkova K, Marcos AT, Gutierrez S. Penicillin and cephalosporin biosynthesis: mechanism of carbon catabolite regulation of penicillin production. Antonie Van Leeuwenhoek. 1999 Jan-Feb;75(1-2):21-31. Review. ) or the switch on/off systems earlier cited for down regulation of the expression of genes involved in NHR.
According to a prefenred embodiment, the genes involved in the HR pathway, which are modified are the following genes or homologues thereof: RAD51 , RAD52.
All kinds of mutants having at least one component involved in HR, which is more capable or at least significantly more capable to perform its function in the process of HR are mutants contemplated by the present invention. Preferably, the activity of the components involved in HR has been modified so that the efficiency of the HR pathway is more than 110% of the efficiency in the parent cell it originates from under the same conditions as measured in the assay defined earlier, more preferably more than 200%, most preferably more than 500%. According to a preferred embodiment, the parent organism is one of the filamentous fungi as defined under the sedion host cell. Methods according to the present invention, as extensively but not limiting discussed above, can be used in a wide variety of applications. Some specific applications are described below.
Host cell
Accordingly, the present invention further relates to the filamentous fungus per se, which is preferably used in the method of the invention for increasing the efficiency of targeted integration of a polynucleotide to a pre-determined site into the genome of said filamentous fungal cell, said filamentous fungus having a preference for NHR, and wherein said polynucleotide has a region of homology with said pre-determined site and said method comprising steering an integration pathway towards HR. The charaderistjcs of the filamentous fungus that can be used in this method have been earlier defined. The filamentous fungus preferably used in the method of the invention is a mutant originating from a parent cell, wherein the ratio of NHR/HR is decreased and/or wherein the efficiency of the NHR pathway has been lowered and/or the effidency of the HR pathway has been elevated in said mutant cell as compared to said ratio and said effidencies in said parent organism under the same conditions. The assay used to determine the ratio NHR/HR and/or the efficiency of the NHR pathway and/or the effidency of the HR pathway has been earlier described .
The host cell of the present invention is a filamentous fungus, which is capable of being transformed with a cloning vector. For most filamentous fungi tested thus far it was found that they could be transformed using transformation protocols developed for Aspergillus (derived from inter alia Tilbum et al. 1983, Gene 26. :205-221). The skilled person will recognise that successful transformation of the filamentous fungal host species is not limited to the use of vectors, selection marker systems, promoters and transformation protocols specifically exemplified herein.
A filamentous fungus is herein defined as a eukaryotic microorganism of the subdivision Eumycotina in filamentous form, i.e. the vegetative growth of which occurs by hyphal elongation. Preferred filamentous fungal host cells are selected from the group consisting of the genera Aspergillus, Trichoderma, Fusarium, Penicillium, and Acremonium.
In a more preferred embodiment of the invention, the filamentous fungal host cell is seleded from the group consisting of Anidulans, A.oryzae, A.sojae, Aspergilli of the A.niger Group, Trichoderma reesei and Penicillium species. Preferably the Penicillium is a Penicillium chrysogenum or Penicillium citrinum spedes.
The A.niger group is herein defined according to Raper and Fennell (1965, In: The Genus Aspergillus, The Williams & Wilkins Company, Baltimore, pp 293-344) and comprises all (black) Aspergilli therein included by these authors. Most preferred filamentous fungal host cells are selected from the group consisting of Aspergilli of the A.niger group, A.oryzae, Trichoderma reesei and Penicillium chrysogenum. According to a preferred embodiment, the parent organism is the deposited filamentous fungus cell Aspergillus niger CBS 513.88, Aspergillus oryzae ATCC 20423, IFO 4177, ATCC 1011, ATCC 9576, ATCC14488-14491, ATCC 11601, ATCC12892, Penicillium chrysogenum CBS -455.95 or or Penicillium citrinum ATCC 38065, Penicillium chrysogenum P2, Acnemonium chrysogenum ATCC 36225 or ATCC 48272, Trichoderma reesei ATCC 26921 or ATCC 56765 or ATCC 26921, Aspergillus sojae ATCC11906, Chrysosporium lucknowense ATCC44006, Claviceps paspali CBS110.22, Claviceps puφurea CBS164.59, Penicillium brevicompactum ATCC 9056, Aspergillus terreus ATCC 20542, Aspergif/us nidulans ATCC 28901 and or derivatives thereof.
According to another preferred embodiment, the filamentous fungal cell of the invention has a ratio NHR/HR, which is at least 200, at least 50, at least 10 as measured by the following assay. Preferably the ratio of the filamentous fungal cell is at least 1, more preferably at least 0.5, even more preferably at least 0.1, even more preferably at least 0.05, even more preferably at least 0.01 even more preferably at least 0.005 even more preferably at least 0.0O1 even more preferably at least 0.0005 even more preferably at least 0.0001 and most preferably at least 0.00001.
According to a more preferred embodiment, the filamentous fungal cell of the invention has a ratio NHR/HR, which is less than 200, even more preferably less than 50, less than 10 as measured by the following assay. Even more preferably the ratio of the filamentous fungal cell is less than 1 , even more preferably less than 0.5, even more preferably less than 0.1 , even more preferably less than 0.05, even more preferably less than 0.01 even more preferably less than 0.005 even more preferably less than 0.001 even more preferably less than O.0005 even more preferably less than 0.0001 and most preferably less than 0.00001.
The ratio of NHR HR is preferably measured by the assay as described in WO 02/052026 (table 2, p23).
Preferably, the filamentous fUngal cell is deficient in a gene encoding a component involved in NHR, and/or has a decreased level of a component involved in NHR.
Even more preferably, the filamentous fungal cell is deficient in at least one of the following genes: hdfA or homologues thereof as identified in SEQ ID NO: 2 or 19, hdfB or homologues thereof as identified in SEQ ID NO: 5, or 22 or both, and/or has, preferably a decreased amount of at least one of the proteins encoded by these genes. Most preferably, the filamentous fungal cell is inducibly deficient at least one of the following genes: hdfA or homologues thereof as identified in SEQ ID NO: 2 or 19, hdfB or homologues thereof as identified in SEQ ID NO: 5, or 22 or both, and/or has, preferably inducibly, a decreased amount of at least one of the proteins encoded by these genes. According to another preferred embodiment, the filamentous fungal cell is such that in its genome, a gene involved in NHR has been replaced by a non-functional gene or by a selection marker or by another gene.
According to another preferred embodiment, the mutant has an increased level of a component involved in HR. The filamentous fungus according to the invention may have been obtained by molecular biology techniques. A filamentous fungus obtained by such a genetic engineering approach is defined as a recombinant filamentous fungus. However, a recombinant filamentous fungus in the context of the invention could have been subjected earlier in time to mutagenesis technique to reach another wanted effect. According to a most preferred embodiment, the filamentous fungus obtained is a recombinant filamentous fungus. Use of the host cell of the invention
According to a preferred embodiment, there is provided a method which comprises at least the steps of introducing a polynucleotide of interest into the filamentous fungus of the invention, for example by the process of transformation or electroporation, and integration of said polynucleotide in the genetic material of said cell. Integration is a complex process wherein a nucleic acid sequence becomes part of the genetic material of a host cell. One step in the process of nudeic add integration is recombination; via recombination nucleic add sequences are exchanged or inserted and the introduced nucleic acid becomes part of the genetic material of a host cell. In principle two different ways of recombination are possible: homologous and illegitimate or NHR. Most (higher) eukaryotes do not or at least not significantly practice HR although the essential proteins to accomplish such a process are available. One reason for this phenomenon is that frequent use of homologous recombination in (higher) eukaryotes could lead to undesirable chromosomal rearrangements due to the presence of repetitive nudeic add sequences. To accomplish HR via a method according to the invention, it is important to provide a polynucleotide, which has homology with a predetermined site. It is clear to a person skilled in the art that the percentage of homology and the length of (a) homologous region(s) play(s) an important role in the process of homologous recombination. The percentage of homology is preferably close to 100%. A person skilled in the art is aware of the fad that lower percentage of homology are also used in the field of homologous recombination, but dependent on, for example, the regions of homology and their overall distribution, can lead to a lower efficiency of HR but are still useful and therefore induded in the present invention. Furthermore, the length of a (nearly) homologous region is approximately 3 kb which is sufficient to direct homologous recombination. At least one homologous region is necessary for recombination but more preferably two homologous regions flanking the nudeic acid of interest are used for targeted integration. The researcher skilled in the art knows how to select the proper percentage of homology, the length of homology and the amount of homologous regions. By providing such a homology a nucleic acid is integrated at every desired position within the genetic material of a host cell. It is clear to a person skilled in the art that the invention as disclosed herein is used to direct any nucleic acid (preferably DNA) to any pre-determined site as long as the length of homology and percentage of homology are high enough to provide/enable HR. Before the present invention was made, a polynucleotide could not have always easily been integrated at every desired position into the genome of a given filamentous fungus. The method according to the invention is applied, for example, to affect the gene function in various ways, not only for complete inactivation but also to mediate changes in Hie expression level or in the regulation of expression, changes in protein activity or the subcellular targeting of an encoded protein. Complete inactivation, which can usually not be accomplished by existing methods such as antisense technology or RNAi technology (Zrenner R, Willmitzer L, Sonnewald U. Analysis of the expression of potato uriciinediphosphate-glucose pyrophosphorylase and its inhibition by antisense RNA. Planta. (1993);190(2):247-52.) is useful for instance for the inactivation of genes controlling undesired side branches of metabolic patJiways, for instance to increase the production of specific secondary metabolites such as (beta-lactam) antibiotics or carotenoids. Complete inactivation is also useful to reduce the production of toxic or unwanted compounds (chrysogenin in Penicillium; Aflatoxin in Aspergillus: MacDonald KD et al,: heterokaryon studies and the genetic control of penicillin and chrysogenin production in Penicillium chrysogenum. J Gen Microbiol. (1963) 33:375-83). Complete inactivation is also useful to alter the morphology of the organism in such a way that the fermentation process and down stream processing is improved.
The invention allows to replace existing regulatory sequences by alternative regulatory sequences to alter expression of endogenous genes (e. g. expression in response to specific inducers.
One aspect of the present invention relates to the replacement of an active gene by an inactive gene according to a method of the invention. Complete inactivation, which can usually not be accomplished by existing methods such as antisense technology or RNAi technology, is useful for instance for the inactivation of genes controlling undesired side branches of metabolic pathways, for instance to increase the quality of bulk products such as starch, or to increase the produdion of specific secondary metabolites or to inhϊ bit formation of unwanted metabolites.
Another aspect of the invention relates to the extensive metabolic reprogramming or engineering of a filamentous fUngal cell. Introdudiori of complete new pathways and/or modification of unwanted pathways will lead to the obtention of a cell specifically adapted for the produdion of a specific compound such as a protein or a metabolite.
Another aspect of the present invention relates to the replacement of an inactive or altered gene by an adive gene. For example, after successive rounds of classical mutagenesis, it often occurs the selected filamentous fungal strain has some endogenous genes altered or even inactivated during the random mutagenesis process.
In yet another aspect of the invention there is provided a method to introduce a substance conferring resistance for an antibiotic substance to a filamentous fungal cell. In yet a further aspect of the invention, there is provided a method to confer a desired property to a filamentous fungal cell. In a preferred embodiment a gene delivery vehicle is used to deliver a desired polynucleotide to a predetermined site. Gene delivery vehides are well known in the art and have been earlier described in the description.
Also another preferred method according to a further aspect of the invention is to effectuate predictable expression of transgenes encoding novel products, for example by replacing existing coding sequences of genes giving a desired expression profile by those for a desired novel product. According to a more preferred embodiment, the filamentous fungus provided by the invention further comprises a DNA construct comprising a desired gene coding for a desired protein to be produced. Preferably, the desired gene encoding the desired protein to be produced is inserted into an expression vector, which is subsequentiy used to transform the obtained host cell. In the expression vector, the DNA sequence may be operationally linked to appropriate expression signals, such as a promoter, optionally a signal sequence and a terminator, which are capable of directing the expression and synthesis of the protein in the host organism.
More preferably, the desired gene is operationally linked to a promoter and to a secretion signal. The strategy, which can be used to express the desired gene is the same as the one described under the sedion up regulation of the expression of a DNA sequence, whose expression product is involved in HR: increasing copy number, targeting integration, use of a promoter of a highly expressed gene, choice of the selection marker gene and combinations thereof. The desired protein is preferably an enzyme. If the protein is not naturally secreted, the polynuclelotide encoding the protein may be modified to have a signal sequence in accordance with techniques known in the art. The proteins, which are secreted may be endogenous proteins which are expressed naturally, but can also be heterologous. Heterologous means that the gene encoded by the protein is not produced under native condition in the wild type filamentous fungus. Examples of enzymes which may be produced by the filamentous fungi of the invention are carbohydrases, e.g. cellulases such as en oglucanases, β-glucanases, cellobiohydrolases or β-glucosidases, hemicellulases or pectinolytic enzymes such as xylanases, xylosidases, mannanases, galadanases, galactosidases, rhamnogaladuronases, arabanases, galacturonases, lyases, or amylolytic enzymes; phosphatases such as phytases, esterases such as lipases, proteolytic enzymes, oxidoreductases such as oxidases, transferases, or isomerases. More preferably, the desired gene encodes a phytase.
As another example existing coding sequences are modified so that the protein encoded has optimized charaderistics for instance to make a protein with improved thermal charaderistics and/or improved kinetic properties (Km, Kcat), and/or improved enzyme stability, and/or extended substrate range, and/or increased life span, etc. The invention further relates to the use of the filamentous fungus of the invention for producing a polypeptide of interest. Atematively, the filamentous fungus obtained may be used for produdng a secondary metabolite. Preferred secondary metabolites are carotenoid compounds, beta-lactam compounds, drugs, anti-tumor co pounds, etc.
Preferably, the filamentous fungus as obtained in the present invention is used for producing the desired protein by culturing the transformed host cell under conditions condudve to the expression of the DNA sequence encoding the desired protein, and recovering the desired protein as described forexample in the following references: - Li, Z. J., Shukla, V., Fordyce, A. P., Pedersen, A. G., Wenger, K. S., Marten, M. R. Fungal morphology and fragmentation behavior in a fed-batch Aspergillus oryzae fermentation at the production scale. Biotechnol Bioeng. 2000 Nov 5;70(3):300-12 Withers, J. M., Swift, R. J., Wiebe, M. G., Robson, G. D., Punt, P. J., van den Hondel, C. A. Optimization and stability of glucoamylase produdion by recombinant strains of Aspergillus niger in chemostat culture. Biotechnol Bioeng. 1998 Aug 20;59(4):407-18.
Amanullah, A., Christensen, L. H., Hansen, K., Nienow, A. W., Thomas, R. C. Dependence of morphology on agitation intensity in fed-batch cultures of Aspergillus oryzae and its implications for recombinant protein production. Biotechnol Bioeng.2002 Mar 30;77(7):815-26.
DNA sequences and polypeptides encoded by these DNA sequences
According to a further aspect of the invention, there are provided the following isolated cDNA sequences:
SEQ ID NO: 2 hdfA from A. niger, SEQ ID NO: 19 hdfA from Penicillium chrysogenum
SEQ ID NO: 5 hdfB from A niger
SEQ ID NO: 22 hdfB from Penicillium chrysogenum and homologues thereof.
Each SEQ ID NO: 1, 18, 4 and 21 corresponds respectively to the genomic DNA sequence associated with each cDNA sequence given above.
Each SEQ ID NO: 3, 20, 6 and 23 corresponds respectively to the protein sequence encoded by the respective cDNA sequence given above.
The sequence information as provided herein should not be so narrowly construed as to require inclusion of erroneously identified bases. The spedfic sequences disclosed herein can be readily used to isolate the complete gene from filamentous fungi, in particular A niger or Penicillium chrysogenum which in turn can easily be subjected to further sequence analyses thereby identifying sequencing errors.
Unless otherwise indicated, all nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer and all arnino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nudeotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the adual sequence will cause a frame shift in translation of the nucleotide sequence such that the predided amino acid sequence encoded by a determined nudeotide sequence will be completely different from the amino acid sequence adually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.
The person skilled in the art is capable of identifying such erroneously identified bases and knows how to correct for such errors.
"Homologous" is below defined. Homologous can be understood as meaning derived from other filamentous fungus than Aspergillus niger or Penicillium chrysogenum. Full length DNA from other organisms can be obtained in a typical approach, using cDNA or genomic DNA libraries constructed from other organisms, e.g. filamentous fungi, in particular from the species Aspergillus or Penicillium by screening them.
The invention also encompasses paralogues of hdfA and/or hdfB n the context of the invention, paralogues means DNA sequences homologous to SEQ ID NO: 1 or SEQ D NO: 4 or SEQ ID NO: 18 or SEQ ID NO: 21 and derived from A niger or Penicillium chrysogenum respectively. For example, Aspergillus or Penicillium strains can be screened for homologous hdfA and/or hdfB polynucleotides by Northern blot analysis. Upon detection of transcripts homologous to polynucleotides according to the invention, cDNA libraries can be constructed from RNA isolated from the appropriate strain, utilizing standard techniques well known to those of skill in the art. Alternatively, a total genomic DNA library can be screened using a probe hybridisable to an hdfA and/or hdfB polynucleotide according to the invention. Homologous gene sequences can be isolated, for example, by performing PCR using two degenerate oligonucleotide primer pools designed on the basis of nucleotide sequences as taught herein.
The template for the reaction can be cDNA obtained by reverse transcription of mRNA prepared from strains known or suspeded to express a polynucleotide according to the invention. The PCR product can be subcloned and sequenced to ensure that the amplified sequences represent the sequences of a new hdfA and/or hdfB nucleic acid sequence, or a fundional equivalent thereof.
The PCR fragment can then be used to isolate a full-length cDNA clone by a variety of known methods. For example, the amplified fragment can be labeled and used to screen a bacteriophage or cosmid cDNA library. Alternatively, "the labeled fragment can be used to screen a genomic library.
PCR technology also can be used to isolate full-length cDNA sequences from other organisms. For example, RNA can be isolated, following standard procedures, from an appropriate cellular or tissue source. A reverse transcription reaction can be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis.
The resulting RNA/DNA hybrid can then be "tailed" (e.g., with guanines) using a standard terminal transferase reaction, the hybrid can be digested with RNase H, and second strand synthesis can then be primed (e.g., with a poly-C primer). Thus, cDNA sequences upstream of the amplified fragment can easily be isolated. For a review of useful cloning strategies, see e.g. Sambrook et al., vide supra and Ausubel et al., vide infra.
"Homologous" can also be understood as meaning functional equivalents.
The terms "functional equivalents" and "fundional variants" are used interchangeably herein. Functional equivalents of hdfA and/or hdfB DNA are isolated DNA fragments that encode a polypeptide that exhibits a particular function of the hdfA and/or hdfB. A fundional equivalent of an hdfA and/or hdfB polypeptide according to the invention is a polypeptide that exhibits at least one fundion as part of the NHR complex. Functional equivalents therefore also encompass biologically active fragments.
Functional protein or polypeptide equivalents may contain only conservative substitutions of one or more amino adds of sequences having SEQ ID NO: 3 or 6 or 20 or 23 or substitutions, insertions or deletions of non-essential amino acids. Accordingly, a non-essential amino add is a residue that can be altered in one of these sequences without substantially altering the biological function. For example, amino acid residues that are conserved among the hdfA and/or hdfB proteins of the present invention, are predided to be particularly unamenable to alteration. Furthermore, amino acids conserved among the hdfA and/or hdfB proteins according to the present invention are not likely to be amenable to alteration.
The term "conservative substitution" is intended to mean that a substitution in which the amino acid residue is replaced with an amino acid residue having a similar side chain. These families are known in the art and include amino acids with basic side chains (e.g.lysine, arginine and hystidine), acidic side chains (e.g. aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagines, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine tryptophan, histidine).
Functional nudeic acid equivalents may typically contain silent mutations or mutations that do not alter the biological function of encoded polypeptide. Accordingly, the invention provides nucleic acid molecules encoding hdfA and/or hdfB proteins that contain changes in amino acid residues that are not essential for a particular biological activity. Such hdfA and/or hdfB proteins differ in amino acid sequence from SEQ ID NO: 3 or 6, or 20 or 23 and yet retain at least one of their biological activities. In one embodiment the isolated nudeic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises a substantially homologous amino acid sequence of at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino add sequence shown in SEQ ID NO 3 or 6 or 20 or 23. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J.U. et al., Science 247:1306-1310 (1990) wherein the authors indicate that there are two main approaches for studying the tolerance of an amino acid sequence to change. The first method relies on the process of evolution, in which mutations are either accepted or rejected by natural selection. The second approach uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene and seleds or screens to identify sequences that maintain functionality. As the authors state, these studies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which changes are likely to be permissive at a certain position of the protein. Ror example, most buried amino acid residues require non-polar side chains, whereas few features of surface side chains are generally conserved. Other such phenotypically silent substitutions are described in Bowie et al. and the references cited therein.
An isolated nucleic acid molecule encoding an hdfA and/or hdfB protein homologous to the protein according to SEQ ID ND: 3 or 6 or 20 or 23 can be created b>y introdudng one or more nucleotide substitutions, additions or deletions into the coding nucleotide sequences according to SEQ ID NO: 2 or SEQ ID NO: 5, or SEQ ID NO: 19 or SEQ ID NO: 22 such that one or more amino acid substitutions, deletions or insertions are introduced into the encoded protein. Such mutations may be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis.
The term "functional equivalents" also encompasses orthologues of the . niger hdfA and/or hdfB protein. Orthologues of the A niger hdfA and/or hdfB protein are proteins that can be isolated from other strains or species and possess a similar or identical biological activity. Such orthologues can readily be identified as comprising an amino acid sequence that is substantially homologous to SEQ ID NO: 3 or 6 or 20 or 23.
"Homologous" can also be understood as meaning "substantially homologous". The term "substantially homologous" refers to a first amino add or nudeotide sequence which contains a sufficient or minimum number of identical or equivalent (e.g., with similar side chain) amino acids or nucleotides to a second amino acid or nucleotide sequence such that the first and the second amino acid or nucleotide sequences have a common domain. For example, amino acid or nucleotide sequences which contain a common domain having about 45%, preferably about 50%, preferably about 60%, preferably about 65%, more preferably about 70%, even more preferably aboit 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity or more are defined herein as sufficiently identical.
Also, nucleic acids encoding other hdfA and/or hdfB family members, that have a nucleotide sequence that differs from SEQ ID NO: 2 or 5 or 19 or 22, are within the scope of the invention. Moreover, nucleic acids encoding hdfA and/or hdfB proteins from different species, which thus have a nucleotide sequence which differs from SEQ ID NO: 2 or 5 or 19 or 22. Nucleic add molecules corresponding to variants (e.g. natural allelic variants) and homologues of the hdfA and/or hdfB DNA of the invention can be isolated based on their homology to the hdfA and/or hdfB nudeic acids disclosed herein using the cDNAs disclosed herein or a suitable fragment thereof, as a hybridisation probe according to standard hybridisation techniques preferably under highly stringent hybridisation conditions. "Stringency" of hybridization readions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting -temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature, which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al, Current Protocols in Molecular Biology, Wiley Intersciencet Publishers, (1995).
"Stringent conditions" or "high stringency conditions", as defined herein, may be identified by those that (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride / 0.0015 M sodium citrate / 0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1 % bovine serum albumin / 0.1 *% Ficdl / 0.1 % polyvinylpyrrolidone / 50mM sodium phosphate buffer at pH 6.5 with 750* mM sodium chloride, 75 mM sodium citrate at 42°C ; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1 % sodium pyrophosphate, 5 x Denhardfs solution, sonicated salmon sperm DNA (50 Rg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium dtrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.
"Moderately stringent conditions" may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and indude the use of washing solution and hybridization conditions (e. g., temperature, ionic strength and % SDS) less stringent that those described above. An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardfs solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50 C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate fadors such as probe length and the like, or by using an algorithm suitable for determining sequence similarity.
Homologous (similar or identical) sequences can also be determined by using a "sequence comparison algorithm". Optimal alignment of sequences for comparison can be conduded, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl.
Math. 2: 482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J.
Mol. Biol.48: 443 (1970), by the search for similarity method of Pearson & Lipman, Proc.
Nafl Acad. Sci. USA 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software
Package, Genetics Computer Group, 575 Science Dr., Madison, Wl), or by visual inspection. An example of an algorithm that is suitable for determining sequence similarity is the BLAST algorithm, which is described in Altschul, et al., J. Mol. Biol. 215:
403-410 (1990).
Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www. ncbi. nlm. nih. gov ). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. These initial neighborhood word hits ad as starting points to find longer HSPs containing them. The word hits are expanded in both directions along each of the two sequences being compared for as far as the cumulative alignment score can be increased. Extension of the word hits is stopped when: the cumulative alignment score fells off by the quantity X from a maximum achieved value; the cumulative score goes to zero or below; or the end of either sequence is reached.
The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment The BLAST program uses as defaults a wordlength (W) of 11, the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sd. USA 89: 10915 (1989)) alignments (B) of 50, expedation (E) of 10, M=5, N= , and a comparison of both strands.
The BLAST algorithm then performs a statistical analysis of the similarity between two sequences (see, e. g., Kariin & Altschul, Proc. Nat'l. Acad. Sd. USA 90: 5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P (N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, an amino add sequence is considered similar to a protein such as a protease if the smallest sum probability in a comparison of the test amino acid sequence to a protein such as a protease amino acid sequence is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001. Preferably the similarity is at least 40% homology to one of the DNA sequences having SEQ ID NO:2, 5, 19 and 22. More preferably the similarity is at least 50%, more preferably, at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90%.
In addition to naturally occurring allelic variants of the hdfA and/or hdfB sequence, the skilled person will recognise that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO: 2 or 5 or 19 or 22, thereby leading to changes in the amino acid sequence of the hdfA and/or hdfB protein without substantially altering the function of the hdfA and/or hdfB protein. In another asped of the invention, deteriorated hdfA and/or hdfB proteins are provided. Deteriorated hdfA and/or hdfB proteins are proteins, wherein at least one biological activity is decreased. Such proteins may be obtained by randomly introducing mutations along all or part of the hdfA and/or hdfB coding sequence, such as by saturation mutagenesis, and the resulting mutants can be expressed recombinantly and screened for biological adivity. For instance, the art provides for standard assays for measuring their enzymatic activity and thus deteriorated proteins may easily be seleded. Preferably, the assay is the one described earlier on (see for example WO02/052026 page 23 or the phenotypic screening assay).
In a preferred embodiment, the hdfA and/or hdfB protein has an amino acid sequence according to SEQ ID NO: 3 or 6 or 20 or 23. In another embodiment, the hdfA and/or hdfB polypeptide is substantially homologous to the amino add sequence according to SEQ ID NO: 3 or 6 or 20 or 23 and retains at least one biological adivity of a polypeptide according to SEQ ID NO:3 or 6 or 20 or 23, yet differs in amino acid sequence due to natural variation or mutagenesis as described above.
In a further preferred embodiment, the hdfA and/or hdfB protein has an amino acid sequence encoded by an isolated nucleic acid fragment capable of hybridising to a nudeic acid according to SEQ ID NO: 2 or 5 or 19 σ 22, preferably under highly stringent hybridisation conditions.
Accordingly, the hdfA and/or hdfB protein is a protein which comprises an amino acid sequence at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 3 or 6 or 20 or 23 and retains at least one fundional adivity of the polypeptide according to SEQ ID NO: 3 or 6 or 20 or 23.
Fundional equivalents of a protein according to the invention can also be identifed e.g. by screening combinatorial libraries of mutants, e.g. truncation mutants, of the protein of the invention for a given activity. In one embodiment, a variegated library of variants is generated by combinatorial mutagenesis at the nucleic add level. A variegated library of variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential protein sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display). There are a variety of methods that can be used to produce libraries of potential variants of the polypeptides of the invention from a degenerate oligonucleotide sequence. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang (1983) Tetrahedron 39:3; Itakura et al. (1984) Annu. Rev. Biochem. 53:323; Itakura et al. (1984) Sdence 198:1056; Ike et al. (1983) Nucleic Add Res. 11:477).
In addition, libraries of fragments of the coding sequence of a polypeptide of the invention can be used to generate a variegated population of polypeptides for screening a subsequent selection of variants. For example, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of the coding sequence of interest with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked produds, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vedor. By this method, an expression library can be derived which encodes Nterminal and internal fragments of various sizes of the protein of interest
Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations of truncation, and for screening cDNA libraries for gene products having a seleded property. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically indude cloning the gene library into replicable expression vedors, transforming appropriate cells with the resulting library of vedors, and expressing the combinatorial genes under conditions in which detection of a desired activity fadlitates isolation of the vedor encoding the gene whose product was deteded. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify variants of a protein of the invention (Arkin and Yourvan (1992) Proc. Natl. Acad. Sci. USA 89:7811- 7815; Delgrave et al. (1993) Protein Engineering 6(3):327-331). In addition to the hdfA and/or hdfB gene sequences shown in SEQ ID NO: 2 and 5 and 19 and 22, it will be apparent for the person skilled in the art that DNA sequence polymorphisms that may lead to changes in the amino acid sequence of the hdfA and/or hdfB protein may exist within a given population. Such genetic polymorphisms may exist in cells from different populations or within a population due to natural allelic variation. Allelic variants may also include functional equivalents.
Fragments of a polynucleotide according to the invention may also comprise polynucleotides not encoding fundional polypeptides. Such polynucleotides may function as probes or primers for a PCR reaction.
Nudeic adds according to the invention irrespective of whether they encode functional or non-functional polypeptides, can be used as hybridization probes or polymerase chain reaction (PCR) primers. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having an hdfA and/or hdfB adivity include, inter alia, (1) isolating the gene encoding the hdfA and/or hdfB protein, or allelic variants thereof from a cDNA library e.g. from other organisms than A niger or Penicillium chrysogenum; (2) in situ hybridization (e.g. FISH) to metaphase chromosomal spreads to provide precise chromosomal location of the hdfA and/or hdfB gene as described in Verma et al., Human Chromosomes: a Manual of Basic Techniques, Pergamon Press, New York (1988); (3) Northern blot analysis for deteding expression of hdfA and/or hdfB mRNA in specific tissues and/or cells and 4) probes and primers that can be used as a diagnostic tool to analyse the presence of a nucleic acid hybridisable to the hdfA and/or hdfB probe in a given biological (e.g. tissue) sample.
Also encompassed by the invention is a method of obtaining a functional equivalent of an hdfA and/or hdfB gene or cDNA. Such a method entails obtaining a labelled probe that includes an isolated nucleic acid which encodes all or a portion of the sequence according to SEQ ID NO: 2 or 5 or 19 or 22 or a variant thereof; screening a nucleic acid fragment library with the labelled probe under conditions that allow hybridisation of the probe to nucleic acid fragments in the library, thereby forming nucleic acid duplexes, and preparing a full-length gene sequence from the nucleic acid fragments in any labelled duplex to obtain a gene related to the hdfA and/or hdfB gene. In one embodiment, an hdfA and/or hdfB nucleic acid of the invention is at least 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more homologous to a nudeic acid sequence shown in SEQ ID NO: 1 , or 2, or 4 or 5 or 18, or 19, or 21 , or 22. In another preferred embodiment an hdfA and/or hdfB polypeptide of the invention is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more homologous to the amino acid sequence shown in SEQ ID NO: 3 or 6 or 20 or 23.
The invention relates to DNA sequences having SEQ ID NO: 1 , or 2, or 4, or 5, or 18, or 19, or 21, or 22 per se and to homologues thereof as defined above. DNA sequences related to these DNA sequences and obtained by degeneration of the genetic code are also part of the invention. DNA sequences related to DNA SEQ ID NO: 2, 5, 19, and 22 and obtained by hybridisation (see former paragraph) are also part of the invention. Isolated polypeptide encoded by these DNA sequences or homologues thereof as defined above are also part of the invention. Polypeptides hdfA and hdfB have a fundion involved in NHR. All these polypeptides can be used in the method of the invention to obtain filamentous fungi, which may have improved targeting efficiencies.
The invention will be illustrated in more detail in the following examples. Such examples are not intended to limit the scope of the invention.
EXAMPLES Example 1: Identification of the hdfA and hdfB genes and construction of the deletion vectors.
Genomic DNA oi Aspergillus niger strain CBS513.88 was sequenced and analyzed. Two genes with translated proteins annotated as homologues to KU70 and KU80, were identified and named hdfA and hdfB respedfvely. Sequences of the hdfA and MB loci, comprising the open reading frame (ORF) (with introns) and approximately 1000 bp 5' and 3' of the genes, are shown in sequence listings 1 and 4. Gene replacement vedors for hdfA and hdfB were designed according to known principles and constructed according to routine doning procedures (see figures 1 and 2). In essence, these vedors comprise approximately 1000 bp flanking regions of the hdf ORFs for homologous recombination at the predestined genomic loci. In addition, they contain the A nidulans bi-directional amoS selection marker, in-between dired repeats. The general design of these deletion vedors were previously described in EP635574B and WO 98/46772. Example 2: Inactivation of the hdfA αene in Asoe illus niger.
Linear DNA of deletion vedor pDEL-HDFA (figure 1) was isolated and used to transform Aspergillus niger CBS513.88 using method earlier described (Biotechnology of Filamentous fungi: Technology and Products. (1992) Reed Publishing (USA); Chapter 6: Transformation pages 113 to 156). This linear DNA can integrate into the genome at the hdfA locus, thus substituting the hdfA gene by the amdS gene as depided in figure 3. Transformants were seleded on acetamide media and colony purified according to standard procedures as described in EP635574B. Spores were plated on fluoro- acetamide media to select strains, which lost the amdS marker. Growing colonies were diagnosed by PCR for integration at the hdfA locus and candidate strains tested by Southern analyses for deletion of the hdfA gene. Deletion of the hdfA gene was detedable by ~ 2,2 kb size redudion of DNA fragments covering the entire locus and hybridized to appropriate probes. Approximately 8 strains showed a removal of the genomic hdfA gene from a pool of approximately 400 initial transformants. Strain dHDFA was selected as a representative strain with the hdfA gene inactivated.
Example 3: Inactivation of the hdfB gene in Aspergillus niger. Linear DNA of deletion vedor pDEL-HDFB (figure 2) was isolated and used to transform the Aspergillus niger strain CBS513.88. This linear DNA can integrate into the genome at the hdfB locus, thus substituting the hdfB gene for amdS (figure 4). The same technique of gene replacement was used as the one described in example
2-Transformants wereseleded on acetamide media and colony purified according to standard procedures. Spores were plated on fluoro-acetamide media to seled strains, which lost the amdS marker (EP 635574B). Growing colonies were diagnosed by PCR for integration at the hdfB locus and candidate strains tested by Southern analyses for deletion of the hdfB gene. Deletion of the hdfB gene was detectable by ~ 2,6 kb size reduction of DNA fragments covering the entire locus and hybridized to appropriate probes. Approximately 7 strains showed a removal of the genomic hdfB gene from a pool of approximately 370 initial transformants. Strain dHDFB was seleded as a representative strain with the hdfB gene inactivated. Example 4: Inactivation of the hdfA and hdfB genes in Aspergillus niger
Linear DNA of deletion vedor pDEL-HDFB (figure 2) was isolated and used to transform strain dHDFA. obtained in Example 2. This linear DNA can integrate into the genome at the hdfB locus, thus substituting the hdfB gene for amdS (figure 4). The technique of gene replacement used is the one described in example 2.Transformants were seleded on acetamide media and colony purified according to standard procedures. Spores were plated on fiuoro-acetamide media to select strains, which lost the amdS marker. Growing colonies were diagnosed by PCR for integration at the hdfB locus and candidate strains tested by Southern analyses for deletion of the hdfB gene. Deletion of the hdfB gene was detectable by ~ 2,6 kb size redudion of DNA fragments covering the entire locus and hybridized to appropriate probes. Approximately 15 strains showed a removal of the genomic ΛcffB gene from a pool of approximately 380 initial transformants. Strain dHDFAB was seleded as a representative strain with both the hdfA and hdfB genes inadivated.
Example 5: Improved targeting for single homologous recombination events.
One mechanism by which DNA may integrate into the genome of Aspergillus niger at a predestined locus is through a single homologous recombination. Homologous DNA aligns and integrates at the genomic position by recombination (see figure 5). Two vectors were used to test the targeting efficiency through a single homologous recombination of Aspergillus niger strains obtained in examples 2, 3, and 4. The two vedors comprise regions homologous to the glucoamylase {glaA) locus to dired recombination and resulting integration (figure 5). The first vector designed for such homologous integration has already been earlier described in WO 02/45524 (pGBFIN11-EPO). This vedor contains the gene coding for the praline sp>ecific endoprotease.
The second vedor (pGBFINI 1-PLA) contains the gene coding for phospholipase A1 (PLAI) from A. oryzae. The gene encoding this enzyme has already been published (Watanabe I, et al, Biosd. Biotechnol. Biochem. (1999), Vol 63, numero 5, pages 820- 826). This gene was cloned into pGBFINH using the same technique as described in WO 02/045524 for the cloning of the proline specific endoprotease gene in pGBFIN11- EPO. Strains CBS513.88, dHDFA, dHDFB and dHDFAB were transformed with either pGBFIN11-EPO or pGBFIN11-PLA plasmids according to transformation techniques earlier described in example 2. The results obtained were the same with both plasmids used. We found respectively, 5 %, 10%, 10% and 10%, of transformants with plasmids integrated at the target locus. Hence, we concluded that the inactivation of at least one hdf-gene in Aspergillus niger leads to a significant increase of the targeting efficiency of these strains through a single homologous recombination event.
Example 6: Improved targeting for double homologous recombination events at several different loci.
The targeting efficiency was further assessed by transformation of the dHDFA strain with deletion vectors designed for the inactivation of a number of amylase encoding genes from the genome. Gene-flanking regions were cloned essentially as described in Example 1, and the resulting vedors were linearised and used to transform protoplasts of CBS513.88 and the dHDFA strain. The targeting frequency was assessed by PCR analyses and activity-based plate assays indicative of the inactivation of the corresponding genes. The latter was done by propagating transformants on PDA plates supplemented with 0.4% agar and subsequent staining with an iodine/potassium iodine solution (Lugol, Sigma L 6146). As can be seen in Table 1 below, the targeting frequency, as judged by PCR analyses and/or adivity-based plate assays indicative of the inactivation of the corresponding genes, was significantly improved over that observed with the CBS513.88 strain.
Table 1. Targeting frequencies of several deletion vedors in the dHDFA strain as compared with strain CBS513.88
Figure imgf000043_0001
These findings provide further support for our conclusion that inadivation of at least one of the hdf genes in Aspergillus niger results in a significant increase of the targeting efficiency of vectors for integration through double homologous recombination. Example 7: The effect of size reduction of the homologous flanking regions of the amyBll gene on targeting frequencies.
In a separate series of experiments the effed of flanking region length on the transformation effidency and targeting frequency through double homologous recombination was further investigated. Protoplasts of strains CBS513.88 and dHDFA were transformed with PCR fragments encompassing the A nidulans amdS marker flanked by amyBll flanking regions of variable length. The data shown in Table 2 clearly demonstrate that, in addition to enhanced overall transformation effidencies, targeting of the integrative cassettes was much improved in the dHDFA strain.
Table 2. Transformation efficiency and targeting frequencies of amyBll PCR deletion cassettes of variable length in the dHDFA strain and strain CBS513.88
Figure imgf000044_0001
, not determined ", combined % for three variants tested
Example 8: Phenotvpe analysis and production of polypeptide.
No phenotypic differences were observed during growth of the dHDFA, dHDFB or dHDFAB strains on solid media or shake flasks. Strains dHDFA, dHDFB and dHDFAB transformed with plasmids pGBFIN11-EPO or pBGFIN-PLA all secreted active enzyme into the medium as determined according to the following procedures.
Solid media was the potato dextrose agar (PDA) medium (Difco, POTATO DEXTROSE
AGAR, cultivation medium, catalogus. nr.213400, year 1996-1997).
Shake flask experiments were performed in 100 ml of the medium as described in EP
635 574 B at 34°C and 170 rpm in an incubator shaker using a 500 ml baffled shake flask. After four days of fermentation, samples were taken to determine either the proline specific endoprotease activity or the phospholipase adivity. The proteolytic activity of the proline specific endoprotease was spedrophotometrically measured in time at pH 5 and about 37°C using ZGIy(άne)-
Pro(line)-pNA as a substrate. 1U proline specific endoprotease is defined as the amount of enzyme which converts 1 micromol ZGIy(dne)-Pro(line)-pNA per min at pH 5 and at37°C.
To determine phospholipase PLA1 adivity from Aspergillus niger (PLA1) spedrophotometrically, an artificial substrate is used: 1,2-dithiodioctanoyl phophatidylcholine (diC8, substrate). PLA1 hydrolyses the sulphide bond at the A1 position, dissociating thio-odanoϊc acid. Thio-octanoϊc acid reads with 4,4 dithiopyridine (color reagent, 4-DTDP), forming 4-thiopyridone. 4Thiopyridone is in tautomeric equilibrium with 4-mercaptopyridine, which absorbs radiation having a wavelength of 334 nm. The extinction change at that wavelength is measured. One unit is the amount of enzyme that liberates of 1 nmol thio-octanoϊc acid from 1,2- dithiodiodanoyl phosphatidylcholine per minute at 37°C and pH 4.0.
The substrate solution is prepared by dissolving 1 g diC8 crystals per 66 ml ethanol and add 264 ml acetate buffer. The acetate buffer comprises 0.1 M Acetate buffer pH 3.85 containing 0.2% Triton-X100. The colour reagent is a 11 mM 4,4-dithiodipyridine solution. It was prepared by weighting 5,0 mg 4,4-dithiodipyridine in a 2 ml eppendorf sample cup and dissolving in 1.00 ml ethanol. 1.00 ml of milli-Q water was added.
Interestingly, morphologic changes such as color differences or colony appearance occurred less frequent for transformants obtained from the dHDFA, dHDFB and dHDFAB strains than for transformants obtained from CBS513.88. This could be due to redudion of random integrations (NHR) thus preventing unexpeded phenotypic changes.
Example 9: Isolation of Penicillium mutants with improved efficiency for homologous recombination by mutagenesis To isolate mutants with an improved efficiency of gene targeting a combination of classical mutagenesis and molecular biology was applied. Penicillium chrysogenum (CBS 455.95) spores were obtained from colonies sporulating in YEPD (2% Yeast extrad from Difco, 1% pepton from Difco, 2% glucose). These spores were washed in sterile tap water and 10 ml of a suspension containing 108 conidiospores per ml was subjeded to UV irradiation at 254 nm (Sylvania, 15 Watts Black Light Blue tube, model 2005/095624
45
FT15T8/BLB). UV irradiation was applied for 7.5, 15 or 30 minutes while the suspensions were slowly shaken. These different irradation times were chosen to obtain mild, medium and strong mutation rate levels in the cells. After one hour of recovery in the dark, the cells from these three time points were divided in two equal aliquots. The first sample was directly re-sporulated as earlier described (Hersbach, GJM, Van der Beek, CP and Van Dijck, PWM. The Penicillins: properties, biosynthesis and fermentation. In: Vandamme EJ (ed) Biotechnology of Industrial Antibiotics (pp 45-140). Marcel Dekker, New York) and the other sample was incubated for an extended recovery period in YNB medium (0.67% w/v Yeast Nitrogen Base with amino acids (Difco), 2.0% w/v glucose) for 4 hours at 25 C before sporulation was induced.
Third mutagenized samples were obtained by germinating wild type spores overnight in YNB, followed by two washing steps in sterile tap water and resuspended in sterile tap water. Again UV irradiation was applied for 7.5, 15 and 30 minutes while the suspensions were slowly shaken. These samples were diredly re-sporulated (as described above) after one hour of recovery in the dark.
To seled the wanted mutants from these mutegenesized populations, the mutagenesized populations were inoculated in YEPD medium. After germination the development of cells was followed using standard light microscopy. When the average hyphae of a culture was nicely developing, cells were harvested and incubated with lysing enzymes to obtain protoplasts. Protoplasts were transformed with two DNA fragments carrying expression cassettes of fundional seledion markers, ble and amdS. The gene ble encodes a protein capable of conferring resistance to phleomycin (Kolar M, Punt PJ, van den Hondel CA, Schwab H. Transformation of Penicillium chrysogenum using dominant seledion markers and expression of an Escherichia coli lacZ fusion gene. Gene. 1988;62(1):127-34). The gene amdS encodes a protein enabling cells to grow on acetamide as the sole nitrogen source (as described in EP635 574B). Techniques applied for the transfer of DNA to protoplasts of P. chrysogenum are well known in the art and are described in many references, including Fiπkelstein and Ball (eds.), Biotechnology of filamentous fungi, technology and products, Butterworth- Heinemann (1992); Bennett and Lasure (eds.) More Gene Manipulations in fungi, Academic Press (1991); Turner, in: Pϋhler (ed), Biotechnology, second completely revised edition, VHC (1992). The Ca-PEG mediated protoplast transformation is used as described in EP635574. To select targeted integration of these expression cassettes to specific loci in the Penicillium genome short homologous stretches of DNA were added via PCR on both sides of the DNA fragments. Three types of construd were made: the first type contains homologous stretches of DNA of 30 bp, the second of 50 bp and the third of 100bp. Selection was performed transforming mutants obtained from the nine sporulated batches with two DNA constructs pie and amdS) with 30, 50 or 100 bp homologous stredches defining 27 distind batches.The ble gene was targeted to the niaD locus, thereby disrupting the nitrate reductase gene (Gouka RJ, van Hartingsveldt W, Bovenberg RA, van den Hondel CA, van Gorcom RF. Cloning of the nitrate-nitrite reductase gene cluster of Penicillium chrysogenum and use of the niaD gene as a homologous seledion marker. J Biotechnol. 1991 Sep;20(2):189-99), enabling dired selection of transformants on plates containing chlorate, as cells become esistant to chlorate. The amdS gene was targeted to the sutB locus, thereby disrupting the sulphate permease gene (van de Kamp M, Pizzinini E, Vos A, van der Lende TR, Schuurs TA, Newbert RW, Tumer G, Konings WN, Driessen AJ. Sulfate transport in Penicillium chrysogenum: cloning and characterization of the sutA and sutB genes. J. Baderiol. 1999 Dec;181(23):7228-34), enabling dired selection of transformants on plates containing selenate. Transformants were first seleded on chlorate and then tested for selenate. Furthermore, the presence of the selection markers was demonstrated by growth on plates containing acetamide as sole nitrogen source (EP635574B) and subsequentiy on plates containing phleomycine. As control wild type P. chrysogenum CBS 455.95 was also transformed with the same DNA fragments. Mutants with both seledion markers present and resistant against both chlorate and selenate are strains with improved targeted integration.
I Applicant's or agent's file reference number 24181WO International application No.
INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule Ubis)
A. The indications made below relate to the microorganism referred to in the description on p age 22 line 14 and further.
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet Name of depositary institution CENTRAAL BUREAU VOOR SCHIMMELCULTURES Address of depositary institution (including postal code and country) Uppsalalaan 8 P.O. Box 85167 NI^3508 AD Utrecht The Netherlands Date of deposit 10-08-1988 Accession Number CBS 513.1 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet We inform you that the availability of the microorganism identified above, referred to Rule 13bis PCT, shall be effected only by issue of a sample to an expert nominated by the requester until the publication of the mention of grant of the national patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed to be withdrawn.
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") Aspergillus Niger DS2975
For receiving Office use only This sheet was received with the international application uthorized officer
FormPCTTRO/134 (July 1992)
Figure imgf000048_0001
| Applicant's or agent's file reference number 24181 WO Internationa] application No.
INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule I3bis)
A The indications made below relate to the microorganism referred to in the description on page 22 line 16 and further.
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet Name of depositary institution CENTRAAL BUREAU VOOR SCHIMMELCU TURES Address of depositary institution (including postal code and country) Uppsalalaan 8 P.O. Box 85167 NI^3508 AD Utrecht The Netherlands Dale of deposit 02-06-1995 Accession Number CBS 455.95 C ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet We inform you that the availability of the microorganism identified above, referred to Rule 13bis PCT, shall be effected only by issue of a sample to an expert nominated by the requester until the publication of the mention of grant of the national patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed to be withdrawn.
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)
K SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") DS18541
For receiving Office use only This sheet was received with the international application uthorized officer
Form PCT/RO/134 (July 1992)
Figure imgf000049_0001

Claims

1. Method for increasing the effidency of targeted integration of a polynudeotide to a pre-determined site into the genome of a filamentous fungal cell with a preference for NHR, wherein said polynucleotide has a region of homology with said pre-determined site, comprising steering an integration pathway towards HR.
2. The method of claim 1 , wherein the steering comprises providing a mutant of a parent filamentous fungal cell, wherein the ratio of NHR HR is decreased in the mutant as compared to said ratio in said parent organism measured under the same conditions.
3. The method of claiml or 2, wherein the steering comprises providing a mutant which is deficient in a gene encoding a component involved in NHR, and/or has a decreased level of a component involved in NHR.
4. The method of claim 3, wherein the mutant is, preferably indudbly, deficient in at least one of the following genes: hdfA or homologues thereof, hdfB or homologues thereof, or both, and/or has, preferably indudbly, a decreased amount of at least one of the proteins encoded by these genes.
5. The method of claim 3 or 4, wherein a gene involved in NHR has been replaced by a non-fundional variant
6. The method according to any one of claims 1 to 5, wherein the steering comprises adding an excess of small double stranded polynucleotides to the polynucleotide to be integrated.
7. The method according to any one of claims 1 to 6, wherein the steering comprises decreasing the adivity of at least one protein active in the NHR by adding an inhibitor of said protein(s).
8. The method according to any one of claims 1 to 7, wherein the mutant has an increased level of a component involved in HR.
9. The method according to any one of claims 1 to 8, wherein a filamentous fUngal which has a ratio NHR/HR less than 50, preferably less than 10, even more preferably less than 1, and most preferably less than 0.001 is used.
10. A mutant of a parent filamentous fungal cell, the parent organism having a preference for NHR, wherein the ratio of NHR/HR is decreased in the mutant as compared to said ratio in said parent organism measured under the same conditions.
11. The mutant according to daim 10, wherein the mutant is deficient in a gene encoding a component involved in NHR, and/or has a decreased level of a component involved in NHR.
12. The mutant according to claim 10 or 11, wherein the mutant is, preferably inducibly, deficient in at least one of the following genes: hdfA or homologues thereof, hdfB or homologues thereof, or both, and/or has, preferably inducibly, a decreased amount of at least one of the proteins encoded by these genes.
13. The mutant according to any one of claims 10 to 12, wherein in the genome of the organism a gene involved in NHR has been replaced by a non-functional variant
14. The mutant according to any one of claims 10 to 13, wherein the mutant has an increased level of a component involved in HR.
15. The mutant according to any one of claims 10 to 14, wherein the mutant is a recombinant mutant.
16. A filamentous fungal which has a ratio NHR/HR less than 50, preferably less than 10, even more preferably less than 1, and most preferably less than 0.001.
17. The filamentous fungus according to any one of claims 10 to 16 transformed with a DNA construd comprising a DNA sequence comprising a gene of interest encoding a polypeptide of interest.
18. The filamentous fungus according to any one of claims 10 to 17, wherein the filamentous fungus is an Aspergillus, Penicillium or Trichodermaspecies.
19. The filamentous fungus according to claim 18, wherein the Aspergillus is an Aspergillus niger or an Aspergillus oryzae species.
20. The filamentous fungus according to daim 18, wherein the Penicillium is a Penicillium chrysogenum or Penicillium citrinum species.
21. Method for producing a polypeptide of interest, wherein the filamentous fungus of any one of claim 10 to 20 is used .
22. Method for producing a metabolite, wherein the filamentous fungus of any one of claim 10 to 21 is used.
23. Method according to claim 22, wherein the metabolite is a carotenoid compound or a bete-lactam compound.
24. Isolated DNA sequences having SEQ ID NO: 2 or 5 or 19 or 22 or homologues thereof.
25. Isolated polypeptides encoded by the DNA sequences of claim 24 or homologues thereof.
PCT/EP2005/051464 2004-04-02 2005-03-31 Filamentous fungal mutants with improved homologous recombination efficiency WO2005095624A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA002559827A CA2559827A1 (en) 2004-04-02 2005-03-31 Filamentous fungal mutants with improved homologous recombination efficiency
PL05740129T PL1733040T3 (en) 2004-04-02 2005-03-31 Filamentous fungal mutants with improved homologous recombination efficiency
EP05740129A EP1733040B1 (en) 2004-04-02 2005-03-31 Filamentous fungal mutants with improved homologous recombination efficiency
DE602005023427T DE602005023427D1 (en) 2004-04-02 2005-03-31 FILAMENTOUS MUSHROOM MUTANES WITH IMPROVED HOMOLOGICAL RECOMBINATION EFFICIENCY
DK05740129.1T DK1733040T3 (en) 2004-04-02 2005-03-31 Filamentous fungal mutants with improved homologous recombination efficiency
US10/594,014 US9243043B2 (en) 2004-04-02 2005-03-31 Filamentous fungal mutants with improved homologous recombination efficiency
AU2005229437A AU2005229437A1 (en) 2004-04-02 2005-03-31 Filamentous fungal mutants with improved homologous recombination efficiency
JP2007505561A JP2007530065A (en) 2004-04-02 2005-03-31 Filamentous fungal mutants with improved homologous recombination efficiency
EP18160034.7A EP3351637B1 (en) 2004-04-02 2005-03-31 Filamentous fungal mutants with improved homologous recombination efficiency
CN200580011927.4A CN101218348B (en) 2004-04-02 2005-03-31 Filamentous fungal mutants with improved homologous recombination efficiency
AT05740129T ATE480632T1 (en) 2004-04-02 2005-03-31 FILAMENTOUS FUNGAL MUTANTS WITH IMPROVED HOMOLOGUE RECOMBINATION EFFICIENCY
US14/980,425 US9657301B2 (en) 2004-04-02 2015-12-28 Filamentous fungal mutants with improved homologous recombination efficiency

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04076057.1 2004-04-02
EP04076057 2004-04-02

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/594,014 A-371-Of-International US9243043B2 (en) 2004-04-02 2005-03-31 Filamentous fungal mutants with improved homologous recombination efficiency
EP09176806.9A Previously-Filed-Application EP2172557B1 (en) 2004-04-02 2005-03-31 Filamentous fungal mutants with improved homologous recombination efficiency
US14/980,425 Division US9657301B2 (en) 2004-04-02 2015-12-28 Filamentous fungal mutants with improved homologous recombination efficiency

Publications (2)

Publication Number Publication Date
WO2005095624A2 true WO2005095624A2 (en) 2005-10-13
WO2005095624A3 WO2005095624A3 (en) 2006-02-16

Family

ID=34966505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/051464 WO2005095624A2 (en) 2004-04-02 2005-03-31 Filamentous fungal mutants with improved homologous recombination efficiency

Country Status (12)

Country Link
US (2) US9243043B2 (en)
EP (3) EP2172557B1 (en)
JP (2) JP2007530065A (en)
CN (1) CN101218348B (en)
AT (1) ATE480632T1 (en)
AU (1) AU2005229437A1 (en)
CA (1) CA2559827A1 (en)
DE (1) DE602005023427D1 (en)
DK (1) DK1733040T3 (en)
ES (1) ES2350048T3 (en)
PL (1) PL1733040T3 (en)
WO (1) WO2005095624A2 (en)

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092396A1 (en) * 2005-03-01 2006-09-08 Dsm Ip Assets B.V. Aspergillus promotors for expressing a gene in a fungal cell
WO2007063133A2 (en) 2005-12-01 2007-06-07 Dsm Ip Assets B.V. Genes useful for the industrial production of citric acid
WO2008113847A2 (en) * 2007-03-21 2008-09-25 Dsm Ip Assets B.V. Improved method for homologous recombination
WO2008138835A1 (en) 2007-05-09 2008-11-20 Novozymes A/S Expression cloning method suitable for selecting library clones producing a polypeptide of interest
EP2123772A1 (en) 2008-04-29 2009-11-25 DSM IP Assets B.V. Beta-lactam antibiotic producing strains
WO2010104390A2 (en) 2009-03-11 2010-09-16 Dsm Ip Assets B.V. Preparation of alpha-ketopimelic acid
WO2010102976A1 (en) 2009-03-10 2010-09-16 Dsm Ip Assets B.V. Pregastric esterase and derivatives thereof
WO2010102982A1 (en) 2009-03-10 2010-09-16 Dsm Ip Assets B.V. Method for improving the yield of a polypeptide
WO2010121933A1 (en) 2009-04-22 2010-10-28 Dsm Ip Assets B.V. Process for the production of a recombinant polypeptide of interest
WO2010122141A1 (en) 2009-04-24 2010-10-28 Dsm Ip Assets B.V. Carbohydrate degrading polypeptide and uses thereof
WO2011009700A1 (en) 2009-07-22 2011-01-27 Dsm Ip Assets B.V. Improved host cell for the production of a compound of interest
WO2011054899A1 (en) 2009-11-04 2011-05-12 Dsm Ip Assets B.V. Talaromyces transformants
WO2011095374A2 (en) 2010-02-04 2011-08-11 Dsm Ip Assets B.V. Process for preparing filamentous fungal strains having a sexual cycle and a process for preparing sexually crossed filamentous fungal strains
WO2011098577A1 (en) 2010-02-11 2011-08-18 Dsm Ip Assets B.V. Host cell capable of producing enzymes useful for degradation of lignocellulosic material
WO2011098580A1 (en) 2010-02-11 2011-08-18 Dsm Ip Assets B.V. Polypeptide having cellobiohydrolase activity and uses thereof
EP2336308A3 (en) * 2003-06-25 2011-11-09 Novozymes A/S Enzymes for starch processing
EP2392649A2 (en) 2008-08-05 2011-12-07 DSM IP Assets B.V. Adipoyl-7-ADCA producing strains
WO2012000890A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having beta-glucosidase activity and uses thereof
WO2012001169A1 (en) 2010-07-01 2012-01-05 Dsm Ip Assets B.V. A method for the production of a compound of interest
WO2012000888A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having acetyl xylan esterase activity and uses thereof
WO2012000887A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having swollenin activity and uses thereof
WO2012000892A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof
WO2012000886A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having beta-glucosidase activity and uses thereof
WO2012000891A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having carbohydrate degrading activity and uses thereof
EP2410048A1 (en) 2005-01-24 2012-01-25 DSM IP Assets B.V. Method for producing a compound of interest in a filamentous fungal cell
EP2423315A1 (en) 2006-06-29 2012-02-29 DSM IP Assets B.V. A method for achieving improved polypeptide expression
WO2012031910A2 (en) 2010-09-10 2012-03-15 Dsm Ip Assets B.V. Method for preparing alpha-ketopimelic acid by c1-elongation
EP2458007A1 (en) 2005-11-29 2012-05-30 DSM IP Assets B.V. DNA binding site of a transcriptional activator useful in gene expression
WO2012123429A1 (en) 2011-03-11 2012-09-20 Dsm Ip Assets B.V. Vector-host system
EP2511372A1 (en) 2006-11-02 2012-10-17 DSM IP Assets B.V. Improved production of secreted proteins by filamentous fungi
WO2013076280A1 (en) 2011-11-23 2013-05-30 Dsm Ip Assets B.V. Nucleic acid assembly system
EP2631295A2 (en) 2007-02-15 2013-08-28 DSM IP Assets B.V. A recombinant host cell for the production of a compound of interest
US8569038B2 (en) * 2004-12-06 2013-10-29 Kikkoman Corporation Transformant having an increased frequency of homologous recombination
WO2013189878A1 (en) 2012-06-19 2013-12-27 Dsm Ip Assets B.V. Promoters for expressing a gene in a cell
WO2014013074A1 (en) 2012-07-19 2014-01-23 Dsm Ip Assets B.V. Agse-deficient strain
WO2014118360A2 (en) 2013-02-04 2014-08-07 Dsm Ip Assets B.V. Carbohydrate degrading polypeptide and uses thereof
WO2014142647A1 (en) 2013-03-14 2014-09-18 Wageningen Universiteit Fungals strains with improved citric acid and itaconic acid production
WO2014202621A1 (en) 2013-06-20 2014-12-24 Dsm Ip Assets B.V. Carbohydrate degrading polypeptide and uses thereof
WO2014202622A2 (en) 2013-06-19 2014-12-24 Dsm Ip Assets B.V. Rasamsonia gene and use thereof
WO2014202620A2 (en) 2013-06-19 2014-12-24 Dsm Ip Assets B.V. Rasamsonia gene and use thereof
WO2014202624A2 (en) 2013-06-19 2014-12-24 Dsm Ip Assets B.V. Rasamsonia gene and use thereof
WO2015082488A1 (en) 2013-12-02 2015-06-11 Dsm Ip Assets B.V. Ice structuring protein
US9243043B2 (en) 2004-04-02 2016-01-26 Dsm Ip Assets B.V. Filamentous fungal mutants with improved homologous recombination efficiency
WO2016110512A1 (en) 2015-01-06 2016-07-14 Dsm Ip Assets B.V. A crispr-cas system for a yeast host cell
WO2016110453A1 (en) 2015-01-06 2016-07-14 Dsm Ip Assets B.V. A crispr-cas system for a filamentous fungal host cell
WO2016193292A1 (en) 2015-06-02 2016-12-08 Dsm Ip Assets B.V. Use of ice structuring protein afp19 expressed in filamentous fungal strains for preparing food
WO2017100158A1 (en) * 2015-12-11 2017-06-15 Danisco Us Inc. Methods and compositions for enhanced nuclease-mediated genome modification and reduced off-target site effects
WO2018019948A1 (en) 2016-07-29 2018-02-01 Dsm Ip Assets B.V. Polypeptides having cellulolytic enhancing activity and uses thereof
WO2018114912A1 (en) 2016-12-21 2018-06-28 Dsm Ip Assets B.V. Lipolytic enzyme variants
WO2018114941A1 (en) 2016-12-21 2018-06-28 Dsm Ip Assets B.V. Lipolytic enzyme variants
WO2018114940A1 (en) 2016-12-21 2018-06-28 Dsm Ip Assets B.V. Lipolytic enzyme variants
WO2018114938A1 (en) 2016-12-21 2018-06-28 Dsm Ip Assets B.V. Lipolytic enzyme variants
WO2018166943A1 (en) 2017-03-13 2018-09-20 Dsm Ip Assets B.V. Zinc binuclear cluster transcriptional regulator-deficient strain
WO2018226900A2 (en) 2017-06-06 2018-12-13 Zymergen Inc. A htp genomic engineering platform for improving fungal strains
WO2021089452A1 (en) 2019-11-04 2021-05-14 Dsm Ip Assets B.V. Low volume transfection
US11028401B2 (en) 2018-06-06 2021-06-08 Zymergen Inc. Manipulation of genes involved in signal transduction to control fungal morphology during fermentation and production
EP4019627A1 (en) 2020-12-28 2022-06-29 Koninklijke Nederlandse Akademie van Wetenschappen New enzymes and methods for benzoic acid-related metabolic pathways
EP4032900A1 (en) 2021-01-21 2022-07-27 Koninklijke Nederlandse Akademie van Wetenschappen New enzymes and methods for vanillic acid-related metabolic pathways
US11479779B2 (en) 2020-07-31 2022-10-25 Zymergen Inc. Systems and methods for high-throughput automated strain generation for non-sporulating fungi
WO2023222614A1 (en) 2022-05-16 2023-11-23 Dsm Ip Assets B.V. Lipolytic enzyme variants

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104781405A (en) * 2012-09-28 2015-07-15 Ucb生物制药私人有限公司 Methods for producing recombinant proteins
EP3080275B1 (en) * 2013-12-13 2020-01-15 Cellectis Method of selection of transformed diatoms using nuclease
EP3523415A1 (en) * 2016-10-04 2019-08-14 Danisco US Inc. Protein production in filamentous fungal cells in the absence of inducing substrates
CN111088173B (en) * 2019-12-26 2021-08-20 南京高新工大生物技术研究院有限公司 Aspergillus niger genetically engineered bacterium and construction method and application thereof
WO2021139779A1 (en) * 2020-01-09 2021-07-15 中国科学院分子植物科学卓越创新中心 Optimized method for editing fungal doubled genome in vitro

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000060359A2 (en) * 1999-04-01 2000-10-12 Kudos Pharmaceuticals Limited Interactions of ku polypeptides
WO2001068882A2 (en) * 2000-03-14 2001-09-20 Transkaryotic Therapies, Inc. Methods for homologous recombination
WO2002052026A2 (en) * 2000-12-22 2002-07-04 Universiteit Leiden Nucleic acid integration in eukaryotes

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416212D0 (en) 1984-06-26 1984-08-01 Sturge John & E Ltd Lactase containing compositions
CA1341226C (en) 1988-08-16 2001-05-01 Wim Van Hartingsveldt Gene replacement as a tool for the construction of aspergillus strains
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
ATE238425T1 (en) 1993-07-23 2003-05-15 Dsm Nv SELECTION MARKER GENE-FREE RECOMBINANT STRAINS: METHOD FOR THEIR PRODUCTION AND THE USE OF THESE STRAINS
DK0758020T3 (en) 1995-08-03 2009-04-06 Dsm Ip Assets Bv Amds gene from Aspergillus niger coding for an acetamidase
CN1169961C (en) 1997-04-11 2004-10-06 Dsm公司 Gene conversion as a tool for the construction of recombinant industrial filmentous fungi
DE69940196D1 (en) 1998-04-15 2009-02-12 Hutchinson Fred Cancer Res METHODS AND VECTOR CONSTRUCTS FOR GENERATING TRANSGENIC RODENTS EXPRESSING A HETEROLOGICAL GENE UBIQUITARY
WO2001042442A2 (en) 1999-12-10 2001-06-14 Cytos Biotechnology Ag Activation of endogenous genes by genomic introduction of a replicon
DK1339837T3 (en) 2000-12-07 2008-06-09 Dsm Ip Assets Bv Prolyl endoprotease from Aspergillus Niger
US20080108056A1 (en) * 2001-03-30 2008-05-08 Masayuki Machida Method of Detecting the Expression of Aspergillus Gene
DE10131786A1 (en) 2001-07-04 2003-01-16 Sungene Gmbh & Co Kgaa Recombination systems and methods for removing nucleic acid sequences from the genome of eukaryotic organisms
US20030092183A1 (en) 2001-09-21 2003-05-15 Fisher Katherine E. Rapid creation of gene targeting vectors using homologous recombination in yeast
AU2003231028A1 (en) 2002-04-22 2003-11-03 Novozymes Biotech, Inc. Methods for increasing homologous recombination of a nucleic acid sequence
EP1673380A2 (en) 2003-10-14 2006-06-28 DSM IP Assets B.V. Method for preparing a modified host cell
WO2005082396A2 (en) 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
US20050181509A1 (en) 2004-02-12 2005-08-18 The Penn State Research Foundation Dual selection based, targeted gene disruption method for fungi and fungus-like organisms
JP4050712B2 (en) 2004-02-27 2008-02-20 独立行政法人科学技術振興機構 Method for homologous recombination
EP2172557B1 (en) 2004-04-02 2018-03-14 DSM IP Assets B.V. Filamentous fungal mutants with improved homologous recombination efficiency
JP2006058093A (en) * 2004-08-18 2006-03-02 National Institute For Materials Science Blood analyzer
EP1794305A2 (en) 2004-09-23 2007-06-13 BASF Plant Science GmbH Recombination cassettes and methods for sequence excision in plants
WO2007013979A2 (en) 2005-07-20 2007-02-01 Invitrogen Corporation Methods for increasing efficiency of homologous recombination
DE602007012846D1 (en) 2006-04-08 2011-04-14 Dsm Ip Assets Bv IMPROVED METHOD FOR HOMOLOGOUS RECOMBINATION IN EUKARYONTIC CELLS
EP2126100B1 (en) 2007-03-21 2012-11-14 DSM IP Assets B.V. Improved method for homologous recombination
US8597923B2 (en) 2009-05-06 2013-12-03 SyntheZyme, LLC Oxidation of compounds using genetically modified Candida

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000060359A2 (en) * 1999-04-01 2000-10-12 Kudos Pharmaceuticals Limited Interactions of ku polypeptides
WO2001068882A2 (en) * 2000-03-14 2001-09-20 Transkaryotic Therapies, Inc. Methods for homologous recombination
WO2002052026A2 (en) * 2000-12-22 2002-07-04 Universiteit Leiden Nucleic acid integration in eukaryotes

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
[Online] 15 March 2005 (2005-03-15), XP002346026 Retrieved from the Internet: URL:http://www.fgsc.net/Aspergillus/Asper2program.pdf> [retrieved on 2005-09-21] *
BORKOVICH KATHERINE A ET AL: "Lessons from the genome sequence of Neurospora crassa: Tracing the path from genomic blueprint to multicellular organism." MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, vol. 68, no. 1, March 2004 (2004-03), pages 1-108, XP002346027 ISSN: 1092-2172 *
BOULTON SIMON J ET AL: "Identification of a Saccharomyces cerevisiae Ku80 homologue: Roles in DNA double strand break rejoining and in telomeric maintenance" NUCLEIC ACIDS RESEARCH, vol. 24, no. 23, 1996, pages 4639-4648, XP002346028 ISSN: 0305-1048 *
DATABASE NCBI NIH; 12 March 2003 (2003-03-12), "Neurospora crassa strain OR74A chromosome IV cont3.499" XP002346205 Database accession no. AABX1000206 *
DATABASE NCBI NIH; 12 March 2003 (2003-03-12), "Neurospora crassa strain OR74A cont3.5" XP002346206 Database accession no. AABX01000750 *
NINOMIYA YUUKO ET AL: "Analysis of non-homologous recombination genes, ncku70 and ncku80, in Neurospora crassa" GENES & GENETIC SYSTEMS, vol. 78, no. 6, December 2003 (2003-12), page 463, XP009054253 & 75TH ANNUAL MEETING OF THE GENETICS SOCIETY OF JAPAN; SENDAI, JAPAN; SEPTEMBER 24-26, 2003 ISSN: 1341-7568 *
NINOMIYA YUUKO ET AL: "Highly efficient gene replacements in Neurospora strains deficient for nonhomologous end-joining" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, no. 33, 17 August 2004 (2004-08-17), pages 12248-12253, XP002346025 ISSN: 0027-8424 *
TSUKAMOTO Y ET AL: "Hdf1, a yeast Ku-protein homologue, is involved in illegitimate recombination, but not in homologous recombination" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 24, no. 11, 1996, pages 2067-2072, XP002170162 ISSN: 0305-1048 *

Cited By (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263381B2 (en) 2003-06-25 2012-09-11 Novozyms A/S Enzymes for starch processing
EP2336308A3 (en) * 2003-06-25 2011-11-09 Novozymes A/S Enzymes for starch processing
US9657301B2 (en) 2004-04-02 2017-05-23 Dsm Ip Assets B.V. Filamentous fungal mutants with improved homologous recombination efficiency
US9243043B2 (en) 2004-04-02 2016-01-26 Dsm Ip Assets B.V. Filamentous fungal mutants with improved homologous recombination efficiency
US8569038B2 (en) * 2004-12-06 2013-10-29 Kikkoman Corporation Transformant having an increased frequency of homologous recombination
EP2410048A1 (en) 2005-01-24 2012-01-25 DSM IP Assets B.V. Method for producing a compound of interest in a filamentous fungal cell
WO2006092396A1 (en) * 2005-03-01 2006-09-08 Dsm Ip Assets B.V. Aspergillus promotors for expressing a gene in a fungal cell
EP2458007A1 (en) 2005-11-29 2012-05-30 DSM IP Assets B.V. DNA binding site of a transcriptional activator useful in gene expression
EP2458008A1 (en) 2005-11-29 2012-05-30 DSM IP Assets B.V. DNA binding site of a transcriptional activator useful in gene expression
WO2007063133A2 (en) 2005-12-01 2007-06-07 Dsm Ip Assets B.V. Genes useful for the industrial production of citric acid
EP2423315A1 (en) 2006-06-29 2012-02-29 DSM IP Assets B.V. A method for achieving improved polypeptide expression
EP2511372A1 (en) 2006-11-02 2012-10-17 DSM IP Assets B.V. Improved production of secreted proteins by filamentous fungi
EP2631295A2 (en) 2007-02-15 2013-08-28 DSM IP Assets B.V. A recombinant host cell for the production of a compound of interest
WO2008113847A3 (en) * 2007-03-21 2009-02-12 Dsm Ip Assets Bv Improved method for homologous recombination
EP2592149A1 (en) 2007-03-21 2013-05-15 DSM IP Assets B.V. Improved method for homologous recombination
WO2008113847A2 (en) * 2007-03-21 2008-09-25 Dsm Ip Assets B.V. Improved method for homologous recombination
JP2010525830A (en) * 2007-05-09 2010-07-29 ノボザイムス アクティーゼルスカブ Expression cloning method suitable for selection of library clones producing the polypeptide of interest
WO2008138835A1 (en) 2007-05-09 2008-11-20 Novozymes A/S Expression cloning method suitable for selecting library clones producing a polypeptide of interest
CN101679993A (en) * 2007-05-09 2010-03-24 诺维信公司 Expression cloning method suitable for selecting library clones producing a polypeptide of interest
EP2123772A1 (en) 2008-04-29 2009-11-25 DSM IP Assets B.V. Beta-lactam antibiotic producing strains
EP2392649A2 (en) 2008-08-05 2011-12-07 DSM IP Assets B.V. Adipoyl-7-ADCA producing strains
WO2010102982A1 (en) 2009-03-10 2010-09-16 Dsm Ip Assets B.V. Method for improving the yield of a polypeptide
WO2010102976A1 (en) 2009-03-10 2010-09-16 Dsm Ip Assets B.V. Pregastric esterase and derivatives thereof
WO2010104391A2 (en) 2009-03-11 2010-09-16 Dsm Ip Assets B.V. Preparation of adipic acid
WO2010104390A2 (en) 2009-03-11 2010-09-16 Dsm Ip Assets B.V. Preparation of alpha-ketopimelic acid
WO2010121933A1 (en) 2009-04-22 2010-10-28 Dsm Ip Assets B.V. Process for the production of a recombinant polypeptide of interest
WO2010122141A1 (en) 2009-04-24 2010-10-28 Dsm Ip Assets B.V. Carbohydrate degrading polypeptide and uses thereof
WO2011009700A1 (en) 2009-07-22 2011-01-27 Dsm Ip Assets B.V. Improved host cell for the production of a compound of interest
EP3293264A1 (en) 2009-07-22 2018-03-14 DSM IP Assets B.V. Improved host cell for the production of a compound of interest
WO2011054899A1 (en) 2009-11-04 2011-05-12 Dsm Ip Assets B.V. Talaromyces transformants
WO2011095374A2 (en) 2010-02-04 2011-08-11 Dsm Ip Assets B.V. Process for preparing filamentous fungal strains having a sexual cycle and a process for preparing sexually crossed filamentous fungal strains
WO2011098577A1 (en) 2010-02-11 2011-08-18 Dsm Ip Assets B.V. Host cell capable of producing enzymes useful for degradation of lignocellulosic material
WO2011098580A1 (en) 2010-02-11 2011-08-18 Dsm Ip Assets B.V. Polypeptide having cellobiohydrolase activity and uses thereof
WO2012000887A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having swollenin activity and uses thereof
WO2012000886A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having beta-glucosidase activity and uses thereof
WO2012000892A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof
WO2012000888A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having acetyl xylan esterase activity and uses thereof
WO2012000890A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having beta-glucosidase activity and uses thereof
WO2012000891A1 (en) 2010-06-29 2012-01-05 Dsm Ip Assets B.V. Polypeptide having carbohydrate degrading activity and uses thereof
US8945898B2 (en) 2010-07-01 2015-02-03 Dsm Ip Assets B.V. Recombinant host cell with deficiency in non-ribosomal peptide synthase production
WO2012001169A1 (en) 2010-07-01 2012-01-05 Dsm Ip Assets B.V. A method for the production of a compound of interest
WO2012031910A2 (en) 2010-09-10 2012-03-15 Dsm Ip Assets B.V. Method for preparing alpha-ketopimelic acid by c1-elongation
WO2012123429A1 (en) 2011-03-11 2012-09-20 Dsm Ip Assets B.V. Vector-host system
WO2013076280A1 (en) 2011-11-23 2013-05-30 Dsm Ip Assets B.V. Nucleic acid assembly system
WO2013189878A1 (en) 2012-06-19 2013-12-27 Dsm Ip Assets B.V. Promoters for expressing a gene in a cell
WO2014013074A1 (en) 2012-07-19 2014-01-23 Dsm Ip Assets B.V. Agse-deficient strain
WO2014118360A2 (en) 2013-02-04 2014-08-07 Dsm Ip Assets B.V. Carbohydrate degrading polypeptide and uses thereof
WO2014142647A1 (en) 2013-03-14 2014-09-18 Wageningen Universiteit Fungals strains with improved citric acid and itaconic acid production
WO2014202624A2 (en) 2013-06-19 2014-12-24 Dsm Ip Assets B.V. Rasamsonia gene and use thereof
WO2014202620A2 (en) 2013-06-19 2014-12-24 Dsm Ip Assets B.V. Rasamsonia gene and use thereof
WO2014202622A2 (en) 2013-06-19 2014-12-24 Dsm Ip Assets B.V. Rasamsonia gene and use thereof
WO2014202621A1 (en) 2013-06-20 2014-12-24 Dsm Ip Assets B.V. Carbohydrate degrading polypeptide and uses thereof
WO2015082488A1 (en) 2013-12-02 2015-06-11 Dsm Ip Assets B.V. Ice structuring protein
WO2016110453A1 (en) 2015-01-06 2016-07-14 Dsm Ip Assets B.V. A crispr-cas system for a filamentous fungal host cell
WO2016110512A1 (en) 2015-01-06 2016-07-14 Dsm Ip Assets B.V. A crispr-cas system for a yeast host cell
WO2016193292A1 (en) 2015-06-02 2016-12-08 Dsm Ip Assets B.V. Use of ice structuring protein afp19 expressed in filamentous fungal strains for preparing food
WO2017100158A1 (en) * 2015-12-11 2017-06-15 Danisco Us Inc. Methods and compositions for enhanced nuclease-mediated genome modification and reduced off-target site effects
WO2018019948A1 (en) 2016-07-29 2018-02-01 Dsm Ip Assets B.V. Polypeptides having cellulolytic enhancing activity and uses thereof
WO2018114912A1 (en) 2016-12-21 2018-06-28 Dsm Ip Assets B.V. Lipolytic enzyme variants
WO2018114941A1 (en) 2016-12-21 2018-06-28 Dsm Ip Assets B.V. Lipolytic enzyme variants
WO2018114940A1 (en) 2016-12-21 2018-06-28 Dsm Ip Assets B.V. Lipolytic enzyme variants
WO2018114938A1 (en) 2016-12-21 2018-06-28 Dsm Ip Assets B.V. Lipolytic enzyme variants
WO2018166943A1 (en) 2017-03-13 2018-09-20 Dsm Ip Assets B.V. Zinc binuclear cluster transcriptional regulator-deficient strain
WO2018226900A3 (en) * 2017-06-06 2019-01-17 Zymergen Inc. A htp genomic engineering platform for improving fungal strains
WO2018226900A2 (en) 2017-06-06 2018-12-13 Zymergen Inc. A htp genomic engineering platform for improving fungal strains
US10954511B2 (en) 2017-06-06 2021-03-23 Zymergen Inc. HTP genomic engineering platform for improving fungal strains
US11180753B2 (en) 2017-06-06 2021-11-23 Zymergen Inc. HTP genomic engineering platform for improving fungal strains
US11242524B2 (en) 2017-06-06 2022-02-08 Zymergen Inc. HTP genomic engineering platform for improving fungal strains
US11028401B2 (en) 2018-06-06 2021-06-08 Zymergen Inc. Manipulation of genes involved in signal transduction to control fungal morphology during fermentation and production
US11299741B2 (en) 2018-06-06 2022-04-12 Zymergen Inc. Manipulation of genes involved in signal transduction to control fungal morphology during fermentation and production
WO2021089452A1 (en) 2019-11-04 2021-05-14 Dsm Ip Assets B.V. Low volume transfection
US11479779B2 (en) 2020-07-31 2022-10-25 Zymergen Inc. Systems and methods for high-throughput automated strain generation for non-sporulating fungi
EP4019627A1 (en) 2020-12-28 2022-06-29 Koninklijke Nederlandse Akademie van Wetenschappen New enzymes and methods for benzoic acid-related metabolic pathways
EP4032900A1 (en) 2021-01-21 2022-07-27 Koninklijke Nederlandse Akademie van Wetenschappen New enzymes and methods for vanillic acid-related metabolic pathways
WO2023222614A1 (en) 2022-05-16 2023-11-23 Dsm Ip Assets B.V. Lipolytic enzyme variants

Also Published As

Publication number Publication date
EP3351637B1 (en) 2020-06-10
US9243043B2 (en) 2016-01-26
EP2172557B1 (en) 2018-03-14
EP2172557A8 (en) 2010-06-23
US9657301B2 (en) 2017-05-23
EP1733040A2 (en) 2006-12-20
DK1733040T3 (en) 2010-11-22
AU2005229437A1 (en) 2005-10-13
PL1733040T3 (en) 2011-01-31
CN101218348B (en) 2014-07-30
DE602005023427D1 (en) 2010-10-21
ES2350048T3 (en) 2011-01-17
JP2011152148A (en) 2011-08-11
US20080227145A1 (en) 2008-09-18
CN101218348A (en) 2008-07-09
EP1733040B1 (en) 2010-09-08
WO2005095624A3 (en) 2006-02-16
EP2172557A1 (en) 2010-04-07
ATE480632T1 (en) 2010-09-15
EP3351637A1 (en) 2018-07-25
JP2007530065A (en) 2007-11-01
US20160130589A1 (en) 2016-05-12
CA2559827A1 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
US9657301B2 (en) Filamentous fungal mutants with improved homologous recombination efficiency
EP3491130B1 (en) An assembly system for a eukaryotic cell
US8642290B2 (en) Fungal transcriptional activators useful in methods for producing a polypeptide
US20180023096A1 (en) A crispr-cas system for a lipolytic yeast host cell
Riach et al. Genetic transformation and vector developments in filamentous fungi
US20240263172A1 (en) Crispr transient expression construct (ctec)
AU2005293516A1 (en) Homologous amdS genes as selectable marker
WO2008053018A2 (en) Improved production of secreted proteins by filamentous fungi
WO2020112881A1 (en) Modified filamentous fungal host cells
JP2019122386A (en) Filamentous fungal cell with inactivated component of selective autophagy pathway and method of using the same
WO2020114893A1 (en) Crispr guide-rna expression strategies for multiplex genome engineering
US20220235378A1 (en) Multipartite crispr donor
AU2012211485A1 (en) Filamentous fungal mutants with improved homologous recombination efficiency
US20220389458A1 (en) Low volume transfection
Riach et al. University of St. Andrews, St. Andrews, Fife, Scotland

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2559827

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005740129

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10594014

Country of ref document: US

Ref document number: 2005229437

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007505561

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 200580011927.4

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2005229437

Country of ref document: AU

Date of ref document: 20050331

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005229437

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005740129

Country of ref document: EP